EP0016906A1 - Bone cement and method for its production - Google Patents
Bone cement and method for its production Download PDFInfo
- Publication number
- EP0016906A1 EP0016906A1 EP80100293A EP80100293A EP0016906A1 EP 0016906 A1 EP0016906 A1 EP 0016906A1 EP 80100293 A EP80100293 A EP 80100293A EP 80100293 A EP80100293 A EP 80100293A EP 0016906 A1 EP0016906 A1 EP 0016906A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- tricalcium phosphate
- bone
- implant
- materials
- prepolymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 23
- 239000002639 bone cement Substances 0.000 title description 31
- 238000004519 manufacturing process Methods 0.000 title description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract description 77
- 239000001506 calcium phosphate Substances 0.000 claims abstract description 73
- 239000000463 material Substances 0.000 claims abstract description 46
- 235000019731 tricalcium phosphate Nutrition 0.000 claims abstract description 45
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims abstract description 41
- 229940078499 tricalcium phosphate Drugs 0.000 claims abstract description 41
- 239000011148 porous material Substances 0.000 claims abstract description 32
- 239000002245 particle Substances 0.000 claims abstract description 26
- 238000002513 implantation Methods 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 229920000193 polymethacrylate Polymers 0.000 claims abstract description 4
- 239000007943 implant Substances 0.000 claims description 44
- 210000000988 bone and bone Anatomy 0.000 claims description 29
- 239000000178 monomer Substances 0.000 claims description 25
- 239000000945 filler Substances 0.000 claims description 19
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 14
- 229930182566 Gentamicin Natural products 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 10
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 229920000058 polyacrylate Polymers 0.000 claims description 7
- 238000006116 polymerization reaction Methods 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 230000007547 defect Effects 0.000 claims description 5
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 abstract description 4
- 229920001577 copolymer Polymers 0.000 abstract description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 abstract description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 32
- 229910000389 calcium phosphate Inorganic materials 0.000 description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 19
- 239000004568 cement Substances 0.000 description 18
- 229920000642 polymer Polymers 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 229910052751 metal Inorganic materials 0.000 description 11
- 239000002184 metal Substances 0.000 description 11
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 8
- 230000006835 compression Effects 0.000 description 8
- 238000007906 compression Methods 0.000 description 8
- 239000007858 starting material Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000002131 composite material Substances 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 238000005245 sintering Methods 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000002436 femur neck Anatomy 0.000 description 2
- -1 for example Chemical class 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- GYVGXEWAOAAJEU-UHFFFAOYSA-N n,n,4-trimethylaniline Chemical compound CN(C)C1=CC=C(C)C=C1 GYVGXEWAOAAJEU-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000002685 polymerization catalyst Substances 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- UIERETOOQGIECD-UHFFFAOYSA-N Angelic acid Natural products CC=C(C)C(O)=O UIERETOOQGIECD-UHFFFAOYSA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
- 208000005250 Spontaneous Fractures Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KIZFHUJKFSNWKO-UHFFFAOYSA-M calcium monohydroxide Chemical compound [Ca]O KIZFHUJKFSNWKO-UHFFFAOYSA-M 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 210000002745 epiphysis Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000017525 heat dissipation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000011872 intimate mixture Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000000528 lesser trochanter Anatomy 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- CVPJXKJISAFJDU-UHFFFAOYSA-A nonacalcium;magnesium;hydrogen phosphate;iron(2+);hexaphosphate Chemical group [Mg+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Fe+2].OP([O-])([O-])=O.OP([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O CVPJXKJISAFJDU-UHFFFAOYSA-A 0.000 description 1
- 229960002950 novobiocin Drugs 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical group [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002367 phosphate rock Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052591 whitlockite Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
Definitions
- the invention relates to implant materials based on polymeric acrylates, in particular polymethyl methacrylate, which can be used in particular as bone replacement, bone composite and prosthesis anchoring materials.
- German Offenlegungsschrift 2620890 proposes adding calcium phosphate to the polymer in a ratio of 1 1 to 5: 1, which corresponds to a calcium phosphate content of 50 to 83%. Calcium phosphate is also broken down and resorbed in the body, so that here too a very high porosity arises, which should lead to a durable bond between the implant and the body through regrowth of body tissue.
- the same principle is also used in the prosthesis anchorage described in German Offenlegungsschrift 26 20907, where calcium phosphate particles of 0.5 to 1 mm in diameter are applied as a dense ball bed so that after the absorption of the calcium phosphate a continuous pore system is to be created which is filled by body tissue can.
- a network of gel threads is to be created by admixing an aqueous gel to the polymer mixture, which network can be filled by bone tissue.
- Consistent porosity should also be according to the method described in J. Biomed. Mater. Res. 11, pp. 373-394 (1977) can be achieved, in which a soluble filler is mixed with the cement. It examines sucrose in particular, but calcium phosphate is also mentioned as a filler. These investigations show that a continuous porosity with sufficiently large pores can only be achieved with a content of soluble admixtures from about 40%, which corresponds approximately to the information in DOS 26 20 890 and 26 20 907.
- the invention accordingly relates to implant materials based on polyacrylates or polymethacrylates, which are characterized in that they contain 5 to 35% by weight of resorbable tricalcium phosphate with a particle size between 50 and 300 ⁇ m and an available pore volume of less than 0.1 ml / g contain.
- the invention also relates to the use of resorbable tricalcium phosphate in a particle size between 50 and 300 / um and an available pore volume of less than 0.1 ml / g as an additive to implant materials based on polyacrylates and the use of these implant materials in combating bone defects .
- the invention further relates to a method for producing implant materials based on polyacrylates or polymethacrylates, which is characterized in that the tricalcium phosphate is added to the monomers which trigger the polymerization before or after mixing with the prepolymer and the components are mixed uniformly.
- the composite of the underlying acrylate polymer is not adversely affected by the relatively small proportion of the tricalcium phosphate. Contrary to the results in the J.Biomed cited above. Mater. Res. Is even surprisingly an improvement in compressive strength of the hardened implant materials observed. In addition, the volume shrinkage that can normally be observed during the hardening of conventional bone cements is significantly reduced. The added tricalcium phosphate also improves the heat dissipation during the polymerization process, so that the risk of so-called heat necrosis is significantly reduced.
- a very firm bond is achieved between the implant and body tissue in the implantation materials according to the invention, although there is generally no complete growth of the implant through body tissue, but only the tricalcium phosphate particles lying on the surface of the implant are resorbed and the resulting peripheral porosity Bone tissue is filled.
- the particle size of the tricalcium phosphate according to the invention controls the pore size of this peripheral porosity in such a way that channels are created in dimensions which are particularly advantageous for bone growth. This is the only way to achieve a bony filling of the porosities.
- the absorption of the tricalcium phosphate particles in the border zone leads to a not inconsiderable increase in the contact area and thus to a distribution of the forces acting on the border zone over a larger area.
- these channels are generally only on the surface of the implant that is accessible to the body fluid. However, if several tricalcium phosphate particles happen to be adjacent, these channels extend further into the interior of the implant. This porosity is present on the surface of the implant, which is fast can be filled by bone tissue, despite the relatively small amount of 5 to 35% by weight of tricalcium phosphate, is sufficient to significantly improve the bond between implant and bone.
- tricalcium phosphate which is used in the present application, is to be understood as a generic term for a number of different materials to be described essentially by the chemical formula Ca 3 (P0 4 ) 2 , the ratio Ca to P being approximately 3: 2 .
- the materials to be described only approximately by the formula Ca 3 (P0 4 ) 2 such as, for example, apatite or phosphorite, are also intended to be included.
- the tricalcium phosphate should be resorbable in the body.
- the calcium phosphates obtained in the precipitation processes are generally relatively soft and have a large pore volume, of the order of magnitude of approximately 0.3-0.5 ml / g. These calcium phosphates have both advantages and disadvantages. It is advantageous that such relatively porous calcium phosphates are rapidly absorbed in the body and allow rapid ingrowth of bone tissue into the porosity of the cement that is thereby formed.
- liquid monomers in the porous calcium phosphate can namely be prevented if the pore volume of the calcium phosphate is filled with a physiologically compatible filler which is resorbable by the body and immiscible with the monomer before being mixed with the monomer. This prevents the inclusion of monomers in the porous calcium phosphate.
- suitable such fillers are, for example, glycerol, water or aqueous salt or buffer solutions, ethylene glycol, low molecular weight polyethylene glycols and lower alcohols such as ethanol, n-propanol and isopropanol.
- the available pore volume should preferably be less than 0.1 ml / g.
- a calcium phosphate which has a very low porosity can also be used.
- the pore volume of these materials should be less than 0.1 ml / g, preferably less than 0.05 ml / g. These materials are usually obtained by sintering at temperatures around or above 1000 ° C to about 1500 ° C.
- precipitated porous tricalcium phosphates can also be used as starting materials. These originally relatively soft, porous materials become significantly harder by heating them to about 1200 ° C for about an hour, preferably after prior pressing. At the same time, the pore volume drops drastically to values that are significantly below 0.05 ml / g.
- the tricalcium phosphates in the particle size according to the invention are obtained by methods known per se, e.g. by grinding and sieving.
- the particle size fraction of 50-300 ⁇ m according to the invention can also be e.g. can be obtained by air sifting or sedimentation. Particles in the size of 80-200 ⁇ m are particularly preferred.
- These tricalcium phosphate particles are incorporated into the bone cement in amounts of between 5 and 35% by weight, preferably between 15 and 30% by weight.
- the known bone cements are prepared so that about 2 parts of a finely divided prepolymer containing a polymerization catalyst (e.g. dibenzoyl peroxide), in particular polymethyl methacrylate or a copolymer of methyl acrylate and methyl methacrylate, with about a part of the liquid monomer, e.g. B. methyl acrylate or methyl acrylate or mixtures thereof, which contains an accelerator (e.g. dimethyl-p-toluidine), are mixed to form a moldable mass which is implanted in the body and hardens there.
- a polymerization catalyst e.g. dibenzoyl peroxide
- an accelerator e.g. dimethyl-p-toluidine
- the implantation materials according to the invention are produced in a similar manner.
- the separate components namely the prepolymer containing the polymerization catalyst, the tricalcium which may have been pretreated with a filler phosphate and the monomer containing the accelerator are mixed together.
- two of the three components can also be premixed in such a way that the tricalcium phosphate is either in a mixture with the prepolymer or the monomer and this mixture is then combined with the third component and mixed uniformly.
- the prepolymers used according to the prior art are without exception so-called bead polymers, which have a very smooth, uniform surface. Since no cross-reaction takes place between the monomer and the prepolymer during the hardening of the cement mixture, the prepolymer beads are only enclosed by the newly forming polymer, but not bound to it. This can lead to the prepolymer beads, which are located in the peripheral zones of the implant and are not enclosed on all sides, being relatively easily detached from the implant and washed away into the body, where they e.g. can collect in lymph nodes.
- the implantation materials according to the invention also yield very advantageous results with these conventional bead polymers and these materials are therefore intended to be encompassed by the present invention, preference is given not to using spherical prepolymers, but rather prepolymers which, owing to a "more angular" shape, do not easily form from the later composite let out.
- Prepolymers which are present in irregular granular form or as flakes (flattened balls) or as thread-like cylinders are therefore preferred.
- the prepolymers should have a diameter of about 10-80 ⁇ m, preferably about 40-60 ⁇ m.
- the thread-like cylinders should not exceed 1 - 2 mm in length.
- this filling of the pores can be done in different ways. In any case, this filling of the pores should be carried out in such a way that all the pores are filled, but there is not so much excess filler that it sticks to the tricalcium phosphate particles or later negatively influences the hardening of the implant materials.
- relatively low-viscosity fillers e.g. simply add the calculated or experimentally determined amount to the tricalcium phosphate, the filler being sucked into the pores due to the capillary forces.
- this can also be added to the tricalcium phosphate, dissolved in a low-boiling solvent, and the solvent can then be evaporated.
- relatively volatile fillers there is also the possibility of filling the pores via the vapor phase. For this it is sufficient to use the tricalcium phosphate e.g. to bring in a closed system into contact with the vapors formed above the liquid filler, condensation of the filler taking place in the pores until they are completely filled due to the reduced vapor pressure in the pores due to the capillary forces.
- glycerol As a filler, it has proven advantageous, for example, to add the glycerol dissolved in alcohol to the tricalcium phosphate and then to let the alcohol evaporate.
- the amounts in which the fillers must be used depend on exclusively on the porosity of the tricalcium phosphate used, since, as already mentioned, the pores should be filled as completely as possible.
- a calcium phosphate is used which is so little porous that there is no need to fill the pores.
- an antibiotic can also be added to the implant material according to the invention.
- an admixture of gentamycin is preferred, with which very good results are achieved.
- the use of gentamycin in bone cement is per se known by the DOS 20 22 117. Nevertheless, it was not obvious to add gentamicin to the bone cement according to the invention containing caicium phosphate. From the Antibiotics Guide, 4th edition (1975), p. 373 below to 374 above, it was known that gentamycin was caused by calcium salts, e.g. the effect of phosphate is reduced.
- Additions of about 1-4% by weight have proven to be particularly favorable for gentamycin in known bone cements. Since the release rate of gentamycin from the bone cement according to the invention is surprisingly up to about ten times higher than from the known gentamycin-containing bone cements, this particularly preferred range for the bone cements according to the invention is about 0.1-2% by weight. However, smaller and also higher additions of about 0.02-4% by weight can be preferred for special purposes.
- antibiotics are added to the material according to the invention, other substances, such as e.g. the amino acids known from DOS 26 51 441 and 27 27 535 are added, by means of which a particularly uniform release of the antibiotic is achieved.
- Other antibiotics can of course also be used instead of gentamycin. In principle, all antibiotics are considered which are not damaged by the temperatures occurring during the polymerization, are stable with respect to the plastics used and are released from the plastics in the desired manner.
- the mixing of the components can be done in any suitable container, e.g. a bowl or a mug. Special mixing devices have also been proposed for this purpose. Because of the presence of the relatively heavy calcium phosphate, the mixing must be carried out with particular care in order to achieve a homogeneous distribution of the calcium phosphate in the implant. There is a particular risk of air being stirred into the mass, which is then present in the hardened implant, in particular in the form of air bubbles, and which can reduce its stability. In particular also because of the poor wettability of the calcium phosphate surface by the liquid monomer, air bubbles preferentially accumulate on the calcium phosphate particles, which prevent the calcium phosphate / cement contact and thereby considerably reduce the stability of the hardened implant. The examination of the conventional bone cements has also shown that air bubbles also arise as a result of flow effects around the polymer beads, which usually measure between 50 and 200 ⁇ m. This volume fraction of trapped air bubbles can make up to 15 volume percent in the finished cement.
- Implantation materials that are set so that. after about 6 - are hardened e-15 minutes after mixing of g and-up to approximately 2 to 8 minutes can be processed, are preferably subjected to an increased pressure in the time 1 to 4 minutes.
- the pressures required for this can be achieved by an internal thread of the syringe with moderate effort, so that, for example, female assistants can easily increase the pressures according to the invention between 10 and 45 kp / cm 2 , preferably between 20 and 40 kp / cm 2 produce.
- the pressure is maintained for some time, preferably for about 1-2 minutes.
- the implantation material can then be pressed out of the syringe through a sufficiently wide outlet channel and introduced into the body.
- Implant materials with or without calcium phosphate which are produced under pre-compression a very greatly reduced proportion of air inclusions, these few inclusions only having a very small diameter.
- the implant materials which contain calcium phosphate it is striking that in samples which are produced under pre-compression, there is a firm bond between the polymer and the calcium phosphate, which is not disturbed by air pockets on the calcium sulfate surface. Materials that are produced under pre-compression therefore have a considerably greater strength than those that are introduced directly into the body after mixing. Processing the materials according to the invention with pre-compression is therefore a further essential aspect of the present invention.
- Another advantage of the bone cements according to the invention is the fact that the addition of an X-ray contrast agent can be dispensed with.
- barium sulfate is usually added to the usual bone cements, but this poses relatively large problems due to its toxicity.
- the calcium phosphate contained in the bone cements according to the invention offers a sufficiently strong X-ray absorption so that no additional X-ray contrast agent has to be added.
- the implantation materials according to the invention in particular those which are also produced with pre-compression according to the method according to the invention, can be used very advantageously in combating bone defects. They are used for the implantation of endoprostheses on the one hand, but also for performing so-called composite osteosynthesis and for filling up certain bone defects.
- the mass is compressed from the 1st to the 3rd minute after mixing under a pressure of about 35 kp / cm 2 and can be processed within the first 3 to 6 minutes, can be plastically deformed until about the 8th minute and after about 10 - 11 minutes fixed.
- the cement obtained is very hard and shows no residues of glycerol on the surface. Similar good results are obtained when using 7 ml and especially when using 6 ml of monomer.
- 40 g of the precipitated tricalcium phosphate from Example 1 are mixed with 30 ml of glycerol in 40 ml of absolute alcohol and left to stand in a desiccator for 24 hours to remove the alcohol.
- 5 g of this tricalcium phosphate treated in this way are mixed well with 6 ml of monomer and 10 g of polymer.
- the mass can be very mix well and is sprayable from the 2nd to the 9th minute, kneadable by hand until the 11th minute, warm after about 12 minutes and hardened after about 13 minutes.
- the cement obtained is very hard and the surface is free of glycerine residues. Compression to a pressure of about 35 kp / cm 2 takes place between the 1st and 3rd minute.
- the starting materials A and B are then annealed at 600 °, 900 °, 1200 ° and 1500 ° C for 1 hour each and starting material C is first annealed at 1200 ° g for 3 hours, then roughly divided, compressed again into tablets and for one hour annealed at 1500 ° C.
- the annealed materials can be obtained by crushing and classifying them in all desired particle sizes.
- An arthrotically modified hip joint is opened, the femoral neck is dissected, the capsule is removed, and the femoral head with the femoral neck is resected 1 cm above the trochanter minor at an angle to the horizontal plane of 35 - 45 degrees, the medullary cavity is curetted and prepared with a special milling machine that an artificial metal prosthesis can be fitted.
- a ventilation tube is inserted into the femoral marrow cavity prepared in this way, which extends to below the tip of the prosthesis.
- the bone cement mass prepared in the manner described above is then injected into the rinsed and prepared medullary cavity and then the metal shaft prosthesis is inserted so that the metal shaft is completely surrounded by bone cement and this plastic tube is nowhere perforated.
- This is achieved by implantation angles and resection surfaces preparatory drawings are planned, whereby the location of the immersion of the metal prosthesis in the plastic cement can be determined beforehand.
- the implanted metal prosthesis becomes immovable until the eleventh minute under pressure pressed in. After this time, the bone cement has hardened and the prosthesis is stably implanted.
- the shrinkage gaps occurring in the border zone are so small that with normal bone vascularization the gap is filled up to the bone after no more than 12 weeks, so that the artificial prosthesis can be fully loaded from this point on.
- An arthrotic femoral head that is still well preserved in its outer shape can also be prepared for a so-called cap prosthesis.
- the femoral head is freed of its residual cartilage.
- the cartilage base plate is prepared with a special milling machine so that bleeding bone points become visible.
- the hip cap is adapted in such a way that the bone and cement border zone is primarily subjected to compressive forces, i. H. contrary to the physiological angular position of the femoral head, the cap is valgized and deflected onto the femoral head.
- the femoral head is then dried and the cap prosthesis is coated with a 2 mm thick layer of cement which has been prepared in the manner described in Example 4.
- the cap containing the cement is now put over the well-dried femoral head and pressed firmly.
- the cement that swells out is removed and the cap is held in the carefully planned position until the eleventh minute.
- the metal cap fixed in this way immediately shows a sufficiently stable fit so that the capped femoral head can be repositioned without difficulty into the plastic socket implanted in the pelvis.
- composite osteosynthesis can be used.
- Two fragments in which metal screws can no longer be securely fixed are filled in from the medullary cavity with a bone cement that has been prepared according to Example 4, either directly in the soft cement or after drilling and threading the hardened cement, on this bond of bone and bone cement, a metal plate can be fixed with screws.
- Such a composite osteosynthesis can also be carried out by strengthening the bond between cement and bone by means of an intramedullary metal nail, which thread the fragments as it were. After the cement has hardened, the screws or the metal implants have a firm hold so that the bone can heal quickly. It could be shown that the cement healing does not interfere with bone healing.
- Examples 1-3 are repeated, using instead of the finely divided prepolymer used there a polymer granulate with a particle size of 40-60 ⁇ m.
- Examples 1-3 are repeated, using filament-shaped polymer cylinders with a length of 0.5 to 1 mm and a diameter of about 50 .mu.m instead of the finely divided prepolymer used there.
- a bone cement mixture is prepared from 30 g polymer, 21 ml monomer, 15 g tricalcium phosphate and 0.5 g gentamycin base, from which cylindrical test specimens with a diameter of 25 mm and a height of 10 mm are formed. Such a test specimen is placed in 20 ml of pH 7.4 phosphate buffer. The fluid is changed every 24 hours and examined for its gentamycin content. An analog test piece, which was formed from a mixture of 40 g of polymer, 20 ml of monomer and 0.5 g of gentamycin base, serves as a comparison.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Implantationsmaterialien und Verfahren zu ihrer HerstellungImplantation materials and processes for their manufacture
Die Erfindung betrifft Implantationsmaterialien auf der Basis von polymeren Acrylaten, insbesondere Polymethylmethacrylat, die insbesondere als Knochenersatz-, Knochenverbund- und Prothesenverankerungsmaterialien Verwendung finden können.The invention relates to implant materials based on polymeric acrylates, in particular polymethyl methacrylate, which can be used in particular as bone replacement, bone composite and prosthesis anchoring materials.
Diese auch als Knochenzemente bekannten Imnlantationsmaterialien werden vom Körper nicht resorbiert, sondern nach dem Einwachsen von körpereigenem Gewebe umschlossen. Eine stabile Verbindung Implantat/Körper ist nur dann gegeben, wenn das Implantat "knöchern" einwächst, das heißt also, daß Knochengewebe bis unmittelbar an die Implantatoberfläche reicht. Sehr häufig kommt es jedoch durch biomechanische Überbeanspruchung des Implantats, d.h. auf das Implantat wirkende Biege- und Scherkräfte, die von der relativ kleinen Grenzfläche Implantat/Körper aufgefangen werden müssen, zur Ausbildung von Umbauzonen mit Geflechtknochen und schließlich zur Bildung einer straffen Bindegewebsschicht anstelle von Knochengewebe. Dies führt zu einer Lockerung des Implantats.These implantation materials, which are also known as bone cements, are not resorbed by the body, but instead are surrounded by the body's own tissue after ingrowth. A stable connection between the implant and the body is only given when the implant "bones in", that is, that means that the bone tissue extends right up to the surface of the implant. Very often, however, it occurs due to biomechanical overloading of the implant, i.e. bending and shear forces acting on the implant, which have to be absorbed by the relatively small interface between the implant and the body, to form remodeling zones with braided bones and finally to form a tight connective tissue layer instead of bone tissue. This leads to a loosening of the implant.
Es hat nun nicht an Versuchen gefehlt, diesen Zustand dadurch zu verbessern, daß die Grenzfläche Implantat/Körper vergrößert wird, z.B. dadurch, daß das Implantat mit einer Porenstruktur versehen wird, die es gestattet, daß das Implantat vollständig von Körpergewebe durchwachsen wird. So wird in der deutschen Offenlegungsschrift 2008708 insbesondere für Zahnimplantate vorgeschlagen, dem Acrylpolymeren neben geriebener Wurzelsubstanz von Naturzähnen und gegebenenfalls einem Schäummittel bis zu 30 Gew.% geriebenen "anorganischen Knochen" zuzusetzen. Durch Auflösung des anorganischen Knochens im Körper soll eine hohe Porosität ausgebildet werden, die zu einem festen Verbund mit dem angrenzenden Gewebe führen soll.There has been no lack of attempts to improve this condition by enlarging the implant / body interface, e.g. in that the implant is provided with a pore structure which allows the implant to be completely grown through by body tissue. For example, in German published patent application 2008708 it is proposed, especially for dental implants, to add up to 30% by weight of rubbed "inorganic bones" to the acrylic polymer in addition to the rubbed root substance of natural teeth and optionally a foaming agent. By dissolving the inorganic bone in the body, a high porosity should be formed, which should lead to a firm bond with the adjacent tissue.
In der deutschen Offenlegungsschrift 2620890 wird vorgeschlagen, dem Polymeren Calciumphosphat in einem Mengenverhältnis von 1 1 bis 5 : 1 zuzusetzen, was einem Calciumphosphatanteil von 50 bis 83 % entspricht. Auch Calciumphosphat wird im Körper abgebaut und resorbiere, so daß auch hier eine sehr hohe Porosität entsteht, die durch Nachwachsen von Körpergewebe zu einem haltbaren Verbund Implantat/Körper führen soll. Das gleiche Prinzip ist auch bei der in der deutschen Offenlegungsschrift 26 20907 beschriebenen Prothesenverankerung angewendet wo Calciumphosphatpartikel von 0,5 bis 1 mm Durchmesser so als dichte Kugelschüttung aufgebracht sind, daß nach der Resorption des Calciumphosphat ein durchgehendes Porensystem entstehen soll, das durch Körpergewebe ausgefüllt werden kann.German Offenlegungsschrift 2620890 proposes adding calcium phosphate to the polymer in a ratio of 1 1 to 5: 1, which corresponds to a calcium phosphate content of 50 to 83%. Calcium phosphate is also broken down and resorbed in the body, so that here too a very high porosity arises, which should lead to a durable bond between the implant and the body through regrowth of body tissue. The same principle is also used in the prosthesis anchorage described in German Offenlegungsschrift 26 20907, where calcium phosphate particles of 0.5 to 1 mm in diameter are applied as a dense ball bed so that after the absorption of the calcium phosphate a continuous pore system is to be created which is filled by body tissue can.
Auch bei dem in der deutschen Offenlegungsschrift 2518153 beschriebenen Verfahren soll durch Zumischung eines wäßrigen Gels zu der Polymerenmischung ein Netzwerk aus Gelfäden entstehen, das durch Knochengewebe gefüllt werden kann.In the method described in German Offenlegungsschrift 2518153, too, a network of gel threads is to be created by admixing an aqueous gel to the polymer mixture, which network can be filled by bone tissue.
Eine durchgängige Porosität soll auch nach dem in J. Biomed. Mater. Res. 11, S. 373 - 394 (1977) beschriebenen Verfahren erzielt werden, bei dem ein löslicher Füllstoff dem Zement beigemischt wird. Es wird darin insbesondere Sucrose untersucht, als Füllstoff wird jedoch auch Calciumphosphat genannt. Diese Untersuchungen ergeben, daß eine durchgängige Porosität mit ausreichend großen Poren erst mit einem Gehalt an löslichen Beimengungen ab etwa 40% erreicht wird, was etwa den Angaben in den DOS 26 20 890 und 26 20 907 entspricht,.Consistent porosity should also be according to the method described in J. Biomed. Mater. Res. 11, pp. 373-394 (1977) can be achieved, in which a soluble filler is mixed with the cement. It examines sucrose in particular, but calcium phosphate is also mentioned as a filler. These investigations show that a continuous porosity with sufficiently large pores can only be achieved with a content of soluble admixtures from about 40%, which corresponds approximately to the information in DOS 26 20 890 and 26 20 907.
Allen diesen Knochenzementen fehlt jedoch die erforderliche Stabilität. Im J. Biomed. Mater. Res. 11, 373 - 394 (1977) wird zwar angegeben, daß auch ein Knochenzement mit etwa 40% Sucrosebeimengung noch die Stärke von natürlichem Knochen aufweist. Dies gilt jedoch bestenfalls für eine einmalige Belastung. Bei wiederholter Belastung tritt jedoch sehr schnell eine Ermüdung des "toten" Implantatmaterials ein und es wird brüchig. Eine ausreichende Stabilität wäre bei diesen Implantaten erst erreicht, wenn eine vollständige Durchwachsung stattgefunden hat. Dies würde jedoch viele Monate in Anspruch nehmen und es ist unmöglich, die entsprechenden,Gliedmaße so lange Zeit ruhig zu stellen.However, all of these bone cements lack the required stability. In J. Biomed. Mater. Res. 11, 373-394 (1977) states that even a bone cement with about 40% sucrose admixture still has the strength of natural bone. However, this applies at best to a one-time charge. With repeated loading, however, the "dead" implant material quickly becomes fatigued and becomes brittle. Adequate stability would only be achieved with these implants if there was complete growth. However, this would take many months and it is impossible to immobilize the corresponding limbs for such a long time.
Es bestand also ein Bedürfnis nach einem Implantationsmaterial, das sowohl unmittelbar nach dem Einbringen in den Körper schon eine ausreichende Stabilität aufweist, als auch in kurzer Zeit durch festes Verwachsen mit dem umgebenden Knochengewebe eine gute Langzeitstabilität garantiert.There was therefore a need for an implantation material that had sufficient stability immediately after being introduced into the body and also guaranteed good long-term stability in a short time due to firm growth with the surrounding bone tissue.
Diese Aufgabe wurde durch die vorliegende Erfindung gelöst.This object has been achieved by the present invention.
Es wurde nämlich gefunden, daß man durch Zumischung eines speziellen Tricalciumphosphats in einer bestimmten Menge und vor allem in einer genau definierten Teilchengröße zu den üblichen Knochenzementen auf Acrylatbasis ein Implantationsmaterial erhält , das alle Forderungen bezüglich sowohl der Kurzzeit- als auch der Langzeitstabilität erfüllt.It has been found that by adding a special tricalcium phosphate in a particular In addition to the usual bone cements based on acrylate, the quantity and, above all, in a precisely defined particle size is given an implantation material that fulfills all requirements with regard to both short-term and long-term stability.
Gegenstand der Erfindung sind demgemäß Implantationsmaterialien auf Basis von Polyacrylaten bzw. Polymethacrylaten, die dadurch gekennzeichnet sind, daß sie 5 bis 35 Gew.% resorbierbares Tricalciumphosphat mit einer Teilchengröße zwischen 50 und 300 µm und einem verfügbaren Porenvölumen von weniger als 0,1 ml/g enthalten.The invention accordingly relates to implant materials based on polyacrylates or polymethacrylates, which are characterized in that they contain 5 to 35% by weight of resorbable tricalcium phosphate with a particle size between 50 and 300 µm and an available pore volume of less than 0.1 ml / g contain.
Gegenstand der Erfindung ist auch die Verwendung von resorbierbarem Tricalciumphosphat in einer Teilchengröße zwischen 50 und 300/um und einem verfügbaren Porenvolumen von weniger als 0,1 ml/g als Zusatz zu Implantationsmaterialien auf Basis von Polyacrylaten und die Verwendung dieser Implantationsmaterialien bei der Bekämpfung von Knochendefekten.The invention also relates to the use of resorbable tricalcium phosphate in a particle size between 50 and 300 / um and an available pore volume of less than 0.1 ml / g as an additive to implant materials based on polyacrylates and the use of these implant materials in combating bone defects .
Gegenstand der Erfindung ist ferner ein Verfahren zur Herstellung von Implantationsmaterialien auf Basis von Polyacrylaten bzw. Polymethacrylaten, das dadurch ge kennzeichnet ist, daß man das Tricalciumphosphat vor oder nach dem Mischen mit dem Präpolymeren dem die Polymerisation auslösenden Monomeren zusetzt und die Komponenten gleichmäßig mischt.The invention further relates to a method for producing implant materials based on polyacrylates or polymethacrylates, which is characterized in that the tricalcium phosphate is added to the monomers which trigger the polymerization before or after mixing with the prepolymer and the components are mixed uniformly.
Die besonderen Vorteile der erfindungsgemäßen Implantationsmaterialien liegen darin, daß durch den relativ geringen Anteil des Tricalciumphosphats der Verbund des zugrunde liegenden Acrylatpolymeren nicht negativ beeinflußt wird. Im Gegensatz zu den Ergebnissen in dem oben zitierten J.Biomed. Mater. Res. wird sogar überraschenderweise eine Verbesserung der Druckbelastbarkeit der ausgehärteten Implantationsmaterialien beobachtet. Außerdem ist der normalerweise bei der Aushärtung von üblichen Knochenzementen zu beobachtende Volumenschwund deutlich verringert. Durch das zugesetzte Tricalciumphosphat wird auch die Wärmeableitung während des Polymerisationsprozesses verbessert, so daß die Gefahr von sogenannten Hitzenekrosen dadurch deutlich verringert ist.The particular advantages of the implantation materials according to the invention are that the composite of the underlying acrylate polymer is not adversely affected by the relatively small proportion of the tricalcium phosphate. Contrary to the results in the J.Biomed cited above. Mater. Res. Is even surprisingly an improvement in compressive strength of the hardened implant materials observed. In addition, the volume shrinkage that can normally be observed during the hardening of conventional bone cements is significantly reduced. The added tricalcium phosphate also improves the heat dissipation during the polymerization process, so that the risk of so-called heat necrosis is significantly reduced.
Erstaunlicherweise wird bei den erfindungsgemäßen Implantationsmaterialien ein sehr fester Verbund zwischen Implantat und Körpergewebe erreicht, obwohl es in der Regel nicht zu einer vollständigen Durchwachsung des Implantats durch Körpergewebe kommt, sondern nur die an der Oberfläche des Implantats liegenden Tricalciumphosphatpartikel resorbiert werden und die dadurch entstehende Randporosität durch Knochengewebe gefüllt wird. Durch die erfindungsgemäße Teilchengröße des Tricalciumphosphats wird jedoch die Porengröße dieser Randporosität so gesteuert, daß Kanäle in für das Knochenwachstum besonders vorteilhaften Dimensionen entstehen. Nur dadurch wird eine primär knöcherne Auffüllung der Porositäten erreicht. Durch Resorption der Tricalciumphosphatpartikel in der Grenzzone kommt es zu einer nicht unerheblichen Vergrößerung der Kontaktfläche und dadurch zu einer Verteilung der auf die Grenzzone einwirkenden Kräfte auf eine größere Fläche.Surprisingly, a very firm bond is achieved between the implant and body tissue in the implantation materials according to the invention, although there is generally no complete growth of the implant through body tissue, but only the tricalcium phosphate particles lying on the surface of the implant are resorbed and the resulting peripheral porosity Bone tissue is filled. The particle size of the tricalcium phosphate according to the invention, however, controls the pore size of this peripheral porosity in such a way that channels are created in dimensions which are particularly advantageous for bone growth. This is the only way to achieve a bony filling of the porosities. The absorption of the tricalcium phosphate particles in the border zone leads to a not inconsiderable increase in the contact area and thus to a distribution of the forces acting on the border zone over a larger area.
Diese Kanäle sind, wie bereits erwähnt, in der Regel nur an der der Körperflüssigkeit zugängigen Oberfläche des Implantats. Wenn jedoch zufällig mehrere Tricalciumphosphatpartikel benachbart sind, reichen diese Kanäle auch weiter ins Innere des Implantats. Diese an der Oberfläche des Implantats vorhandene Porosität, die schnell durch Knochengewebe gefüllt werden kann, ist trotz der relativ geringen Menge von 5 bis 35 Gew.% an Tricalciumphosphat ausreichend, um den Verbund Implantat/Knochen wesentlich zu verbessern.As already mentioned, these channels are generally only on the surface of the implant that is accessible to the body fluid. However, if several tricalcium phosphate particles happen to be adjacent, these channels extend further into the interior of the implant. This porosity is present on the surface of the implant, which is fast can be filled by bone tissue, despite the relatively small amount of 5 to 35% by weight of tricalcium phosphate, is sufficient to significantly improve the bond between implant and bone.
Der Begriff Tricalciumphosphat, der in der vorliegenden Anmeldung gebraucht wird, ist als Oberbegriff zu einer Anzahl von verschiedenen im wesentlichen durch die chemische Formel Ca3(P04)2 zu beschreibende Materialien zu verstehen, wobei das Verhältnis Ca zu P annähernd 3:2 beträgt. Neben den reinen Tricalciumphosphaten wie z.B. a - oder B-Whitlockit, sollen jedoch auch die nur annähernd durch die Formel Ca3(P04)2 zu beschreibenden Materialien wie z.B. Apatite oder Phosphorit umfaßt sein. Auf jeden-Fall soll das Tricalciumphosphat im Körper resorbierbar sein.The term tricalcium phosphate, which is used in the present application, is to be understood as a generic term for a number of different materials to be described essentially by the chemical formula Ca 3 (P0 4 ) 2 , the ratio Ca to P being approximately 3: 2 . In addition to the pure tricalcium phosphates such as, for example, a- or B-whitlockite, the materials to be described only approximately by the formula Ca 3 (P0 4 ) 2 , such as, for example, apatite or phosphorite, are also intended to be included. In any case, the tricalcium phosphate should be resorbable in the body.
Diese Materialien sind an sich bekannt und können nach bekannten Verfahren hergestellt werden. Im wesentlichen sind dies Fällverfahren oder Sinterverfahren oder aber eine Kombination solcher Verfahren. Fäll- und Sinterverfahren zur Herstellung der Calciumphosphate sind in den Standardwerken der anorganischen Chemie, z.B. dem Gmelin, beschrieben. Als Ausgangsmaterialien dienen dazu in der Regel lösliche Calciumsalze und lösliche Phosphate oder aber für die Sinterverfahren z.B. CaO, CaOH, CaCO3 und CaHPO4, die mit P2O5 oder aber untereinander zusammengesintert werden.These materials are known per se and can be produced by known processes. These are essentially precipitation processes or sintering processes or a combination of such processes. Precipitation and sintering processes for the production of the calcium phosphates are described in the standard works of inorganic chemistry, for example gmelin. Soluble calcium salts and soluble phosphates are generally used as starting materials, or for the sintering processes, for example CaO, CaOH, CaCO 3 and CaHPO 4 , which are sintered together with P 2 O 5 or with one another.
Die bei den Fällverfahren gewonnenen Calciumphosphate sind in der Regel-relativ weich und weisen ein großes Porenvolumen auf, das in der Größenordnung von etwa 0,3-0,5 ml/g liegt. Diese Calciumphosphate haben sowohl Vor- als auch Nachteile. Vorteilhaft ist, daß solche relativ porösen Calciumphosphate im Körper schnell resorbiert werden und ein schnelles Einwachsen von Knochengewebe in die dadurch gebildeten Porositäten des Zementes gestatten.The calcium phosphates obtained in the precipitation processes are generally relatively soft and have a large pore volume, of the order of magnitude of approximately 0.3-0.5 ml / g. These calcium phosphates have both advantages and disadvantages. It is advantageous that such relatively porous calcium phosphates are rapidly absorbed in the body and allow rapid ingrowth of bone tissue into the porosity of the cement that is thereby formed.
Nachteilig dabei ist jedoch, daß bei der Verarbeitung besondere Maßnahmen ergriffen werden müssen, um zu verhindern, daß sich die Calciumphosphatteilchen mit. moncrerem Acrylat bzw. Methacrylat vollsaugen. Dies ist unerwünscht, da hierdurch die schnelle, vollständige Polymerisation des Monomeren nicht mehr gewährleistet ist und die Gefahr besteht, daß ein höherer Anteil an Restmonomer nach dem Aushärten zurückbleibt und in den Kreislauf des Patienten gelangen kann. Außerdem wird durch das in den porösen Calciumphosphatteilchen polymerisierende Monomere die Resorbierbarkeit des Calciumphosphat herabgesetzt und es kann dadurch nicht zur Ausbildung von Poren in den gewünschten Dimensionen kommen.However, it is disadvantageous that special measures must be taken during processing in order to prevent the calcium phosphate particles from settling. Soak up the acrylic or methacrylate. This is undesirable since the rapid, complete polymerization of the monomer is no longer guaranteed and there is a risk that a higher proportion of residual monomer remains after curing and can get into the patient's circulation. In addition, the resorbability of the calcium phosphate is reduced by the monomer polymerizing in the porous calcium phosphate particles and this does not result in the formation of pores in the desired dimensions.
Diese negativen Eigenschaften der üblichen, porösen Tricalciumphosphate, die eine Resorption weitgehend verhindern können, waren im Stand der Technik und insbesondere in der oben zitierten Publikation im J. Biomed. Mater. Res. nicht erkannt worden, da in dieser Arbeit Implantationsversuche und Versuche, bei denen der Füllstoff aus dem Zement herausgelöst wird, lediglich mit den sehr leicht löslichen und insbesondere unporösen Sucrosekristallen durchgeführt wurden.These negative properties of the conventional, porous tricalcium phosphates, which can largely prevent absorption, were in the prior art and in particular in the publication cited above in J. Biomed. Mater. Res. Was not recognized, since in this work implantation attempts and attempts in which the filler is removed from the cement were only carried out with the very easily soluble and in particular non-porous sucrose crystals.
Ein wesentlicher Aspekt der vorliegenden Erfindung war es deshalb auch, ein Tricalciumphosphat zur Verfügung zu stellen, das diese negativen Eigenschaften nicht besitzt. Auch diese Aufgabe wird durch die vorliegende Erfindung auf überraschende Weise gelöst.It was therefore an essential aspect of the present invention to provide a tricalcium phosphate which does not have these negative properties. This object is also achieved in a surprising manner by the present invention.
Die Aufnahme von flüssigem Monomeren in das poröse Calciumphosphat kann nämlich verhindert werden, wenn das Porenvolumen des Calciumphosphat vor dem Mischen mit dem Monomeren mit einem physiologisch verträglichen, vom Körper resorbierbaren und mit dem Monomeren nicht mischbaren Füllstoff gefüllt wird. Dadurch wird eine Aufnahme von Monomeren in das poröse Calciumphosphat verhindert. Als solche Füllstoffe geeignet sind beispielsweise Glycerin, Wasser bzw.wässerige Salz- oder Pufferlösungen, Äthylenglycol, niedermolekulare Polyäthylenglycole und niedere Alkohole wie Äthanol, n-Propanol und Isopropanol. Vorzugsweise sollte nach dieser Behandlung das verfügbare Porenvolumen weniger als 0,1 ml/g betragen.The inclusion of liquid monomers in the porous calcium phosphate can namely be prevented if the pore volume of the calcium phosphate is filled with a physiologically compatible filler which is resorbable by the body and immiscible with the monomer before being mixed with the monomer. This prevents the inclusion of monomers in the porous calcium phosphate. Suitable such fillers are, for example, glycerol, water or aqueous salt or buffer solutions, ethylene glycol, low molecular weight polyethylene glycols and lower alcohols such as ethanol, n-propanol and isopropanol. After this treatment, the available pore volume should preferably be less than 0.1 ml / g.
Um diese Komplikationen, hervorgerufen durch die poröse Struktur des verwendeten Calciumphosphats auszuschließen, kann jedoch auch ein Calciumphosphat Verwender werden, das eine sehr geringe Porosität aufweist. Das Porenvolumen dieser Materialien sollte unter 0,1 ml/g, vorzugsweise unter 0,05 ml/g liegen. Man erhält diese Materialien in der Regel durch Sinterverfahren bei Temperaturen um oder über 1000 °C bis etwa 1500°C. Als Ausgangsmaterialien können dazu neben den bereits oben erwähnten CaO, Ca(OH)2, CaC03, CaHPO4 und P2O5 auch gefällte poröse Tricalciumphosphate verwendet werden. Diese ursprünglich relativ weichen, porösen Materialien gewinnen schon durch ein etwa einstündiges Erhitzen auf etwa 1200 °C, vorzugsweise nach vorherigem Verpressen, deutlich an Härte. Gleichzeitig geht dabei das Porenvolumen ganz drastisch zurück auf Werte, die deutlich unterhalb 0,05 ml/g liegen.However, in order to rule out these complications caused by the porous structure of the calcium phosphate used, a calcium phosphate which has a very low porosity can also be used. The pore volume of these materials should be less than 0.1 ml / g, preferably less than 0.05 ml / g. These materials are usually obtained by sintering at temperatures around or above 1000 ° C to about 1500 ° C. In addition to the CaO, Ca (OH) 2 , CaC0 3 , CaHPO 4 and P 2 O 5 mentioned above, precipitated porous tricalcium phosphates can also be used as starting materials. These originally relatively soft, porous materials become significantly harder by heating them to about 1200 ° C for about an hour, preferably after prior pressing. At the same time, the pore volume drops drastically to values that are significantly below 0.05 ml / g.
Die gleichen vorteilhaften Eigenschaften bezüglich der Härte und des Porenvolumens erhält man aber auch beim Sintern anderer Ausgangsmaterialien. So erhält man beispielsweise auch beim Zusammensintern eines Gemisches aus Calciumhydrogenphosphat und Calciumcarbonat bei etwa 1200 - 1500 °C ein Material mit einem Porenvolumen, das fast bei 0 liegt. Die Aufnahme von monomerem Acrylat bei der Verarbeitung ist bei diesen Materialien nicht zu befürchten, so daß hier auf eine Vorbehandlung des Calciumphosphats mit den obengenannten Füllmitteln verzichtet werden kann.The same advantageous properties with regard to hardness and pore volume can also be obtained when sintering other starting materials. So you get at for example, when sintering together a mixture of calcium hydrogen phosphate and calcium carbonate at about 1200 - 1500 ° C, a material with a pore volume that is almost 0. The inclusion of monomeric acrylate during processing is not to be feared with these materials, so that pretreatment of the calcium phosphate with the fillers mentioned above can be dispensed with here.
Die Gewinnung der Tricalciumphosphate in der erfindungsgemäßen Teilchengröße geschieht durch an sich bekannte Methoden, z.B. durch Zermahlen und Sieben. Die erfindungsgemäße Teilchengrößenfraktion von 50 - 300 µm kann aber auch z.B. durch Windsichten oder Sedimentieren gewonnen werden. Bevorzugt sind insbesondere Teilchen in der Größe von 80 - 200 µm.The tricalcium phosphates in the particle size according to the invention are obtained by methods known per se, e.g. by grinding and sieving. The particle size fraction of 50-300 μm according to the invention can also be e.g. can be obtained by air sifting or sedimentation. Particles in the size of 80-200 μm are particularly preferred.
Diese Tricalciumphosphatteilchen werden in Mengen zwischen 5 und 35 Gew.-%, vorzugsweise zwischen 15 und 30 Gew.-% in den Knochenzement eingearbeitet. Die bekannten Knochenzemente werden so zubereiten, daß etwa 2 Teile eines feinteiligen, einen Polymerisationskatalysator (z.B. Dibenzoylperoxid) enthaltenden Präpolymerisats, insbesondere Polymethylmethacrylat oder eines Mischpolymerisats aus Methylacrylat und Methylmethacrylat, mit etwa einem Teil des flüssigen Monomeren, z. B. Acrylsäure- oder Methylacrylsäuremethylester oder deren Gemische, das einen Beschleuniger (z.B. Dimethyl-p-toluidin) enthält, zu einer formbaren Masse gemischt werden, die in den Körper implantiert wird und dort aushärtet. Solche Knochenzemente sind z. B. unter dem Warenzeichen Palacos im Handel.These tricalcium phosphate particles are incorporated into the bone cement in amounts of between 5 and 35% by weight, preferably between 15 and 30% by weight. The known bone cements are prepared so that about 2 parts of a finely divided prepolymer containing a polymerization catalyst (e.g. dibenzoyl peroxide), in particular polymethyl methacrylate or a copolymer of methyl acrylate and methyl methacrylate, with about a part of the liquid monomer, e.g. B. methyl acrylate or methyl acrylate or mixtures thereof, which contains an accelerator (e.g. dimethyl-p-toluidine), are mixed to form a moldable mass which is implanted in the body and hardens there. Such bone cements are e.g. B. under the trademark Palacos in trade.
Die Herstellung der erfindungsgemäßen Implantationsmaterialien erfolgt im Prinzip in ähnlicher Weise. Z. B. können die getrennten Komponenten, nämlich das den Polymerisationskatalysator enthaltende Präpolymerisat, das ggf. mit einem Füllstoff vorbehandelte Tricalciumphosphat und das den Beschleuniger enthaltende Monomere zusammengemischt werden. Es kann aber auch eine Vormischung von zweien der drei Komponenten in der Weise erfolgen, daß das Tricalciumphosphat entweder in Mischung mit dem Präpolymeren oder dem Monomeren vorliegt und diese Mischung dann mit der dritten Komponente vereint und gleichmäßig gemischt wird.In principle, the implantation materials according to the invention are produced in a similar manner. For example, the separate components, namely the prepolymer containing the polymerization catalyst, the tricalcium which may have been pretreated with a filler phosphate and the monomer containing the accelerator are mixed together. However, two of the three components can also be premixed in such a way that the tricalcium phosphate is either in a mixture with the prepolymer or the monomer and this mixture is then combined with the third component and mixed uniformly.
Die nach dem Stand der Technik verwendeten Präpolymeren sind ausnahmslos sogenannte Perlpolymerisate, die eine sehr glatte,einheitliche Oberfläche aufweisen. Da beim 'Aushärten der Zementmischung keine Kreuzreaktion zwischen dem Monomeren und dem Präpolymeren stattfindet, werden die Präpolymerkügelchen von dem sich neu bildenden Polymeren lediglich umschlossen, nicht jedoch daran gebunden. Dies kann dazu führen, daß insbesondere in den Randzonen des Implantats liegende, nicht allseitig umschlossene Präpolymerkügelchen relativ leicht aus dem Implantat herausgelöst und in den Körper abgeschwemmt werden, wo sie sich z.B. in Lymphknoten sammeln können.The prepolymers used according to the prior art are without exception so-called bead polymers, which have a very smooth, uniform surface. Since no cross-reaction takes place between the monomer and the prepolymer during the hardening of the cement mixture, the prepolymer beads are only enclosed by the newly forming polymer, but not bound to it. This can lead to the prepolymer beads, which are located in the peripheral zones of the implant and are not enclosed on all sides, being relatively easily detached from the implant and washed away into the body, where they e.g. can collect in lymph nodes.
Obwohl die erfindungsgemäßen Implantationsmaterialien auch mit diesen konventionellen Perlpolymerisaten sehr vorteilhafte Ergebnisse liefern und diese Materialien deshalb von der vorliegenden Erfindung umfaßt sein sollen, werden vorzugsweise nicht kugelförmige Präpolymere verwendet, sondern Präpolymere, die aufgrund einer "eckigeren" Form sich nicht so leicht aus dem späteren Verbund herauslösen lassen. Bevorzugt werden deshalb Präpolymere, die in unregelmäßiger Granulatform oder als Schuppen (plattgedrückte Kugeln) oder als fadenförmige Zylinder vorliegen. Die Präpolymeren sollten einen Durchmesser von etwa 10 - 80µm, vorzugsweise einen solchen von etwa 40 - 60µm, besitzen. Die fadenförmigen Zylinder sollten eine Länge von 1 - 2 mm nicht überschreiten.Although the implantation materials according to the invention also yield very advantageous results with these conventional bead polymers and these materials are therefore intended to be encompassed by the present invention, preference is given not to using spherical prepolymers, but rather prepolymers which, owing to a "more angular" shape, do not easily form from the later composite let out. Prepolymers which are present in irregular granular form or as flakes (flattened balls) or as thread-like cylinders are therefore preferred. The prepolymers should have a diameter of about 10-80 µm, preferably about 40-60 µm. The thread-like cylinders should not exceed 1 - 2 mm in length.
Falls ein poröses T=icalciumphosphat verwendet wird und deshalb eine Vorbehandlung des Tricalciumphosphats mit einem Füllmittel nötig ist, kann dieses Auffüllen der Poren auf verschiedene Weise erfolgen. In jedem Fall sollte diese Auffüllung der Poren so erfolgen, daß zwar alle Poren gefüllt sind, aber nicht so viel überschüssiges Füllmittel vorhanden ist, daß dieses die Tricalciumphosphatteilchen verklebt oder später das Aushärten der Implantationsmaterialien negativ beeinflußt.If a porous T = icalcium phosphate is used and therefore a pretreatment of the tricalcium phosphate with a filler is necessary, this filling of the pores can be done in different ways. In any case, this filling of the pores should be carried out in such a way that all the pores are filled, but there is not so much excess filler that it sticks to the tricalcium phosphate particles or later negatively influences the hardening of the implant materials.
Bei relativ niedrig viskosen Füllmitteln kann z.B. einfach die berechnete oder experimentell ermittelte Menge dem Tricalciumphosphat zugegeben werden, wobei auf Grund der Kapillarkräfte das Füllmittel in die Poren aufgesaugt wird. Bei höher viskosen Füllmitteln kann dieses jedoch auch in einem niedrig siedenden Lösungsmittel gelöst dem Tricalciumphosphat zugegeben werden und das Lösungsmittel dann verdampft werden. Vor allem bei relativ leicht flüchtigen Füllmitteln besteht jedoch auch die Möglichkeit der Porenfüllung über die Dampfphase. Dazu genügt es, das Tricalciumphosphat z.B. in einem geschlossenen System mit den sich über dem flüssigen Füllmittel bildenden Dämpfen in Berührung zu bringen, wobei auf Grund des in den Poren durch die Kapillarkräfte erniedrigten Dampfdrucks eine Kondensation des Füllmittels in den Poren bis zu deren vollständiger Füllung erfolgt.With relatively low-viscosity fillers, e.g. simply add the calculated or experimentally determined amount to the tricalcium phosphate, the filler being sucked into the pores due to the capillary forces. In the case of high-viscosity fillers, however, this can also be added to the tricalcium phosphate, dissolved in a low-boiling solvent, and the solvent can then be evaporated. Especially with relatively volatile fillers there is also the possibility of filling the pores via the vapor phase. For this it is sufficient to use the tricalcium phosphate e.g. to bring in a closed system into contact with the vapors formed above the liquid filler, condensation of the filler taking place in the pores until they are completely filled due to the reduced vapor pressure in the pores due to the capillary forces.
Welche Methode jeweils am vorteilhaftesten ist, hängt von dem jeweils verwendeten Füllmittel ab. Bei der Verwendung von Glycerin als Füllmittel hat es sich beispielsweise als vorteilhaft erwiesen, das Glycerin in Alkohol gelöst dem Tricalciumphosphat zuzugeben und dann den Alkohol abdunsten zu lassen. Die Mengen, in denen die Füllmittel angewendet werden müssen, hängen ausschließlich von der Porosität des verwendeten Tricalciumphosphats ab, da wie bereits gesagt, die Poren möglichst vollständig gefüllt sein sollen. Vorzugsweise wird jedoch ein Calciumphosphat verwendet, das so wenig porös ist, daß sich das Auffüllen der Poren erübrigt.Which method is most advantageous depends on the filler used. When using glycerol as a filler, it has proven advantageous, for example, to add the glycerol dissolved in alcohol to the tricalcium phosphate and then to let the alcohol evaporate. The amounts in which the fillers must be used depend on exclusively on the porosity of the tricalcium phosphate used, since, as already mentioned, the pores should be filled as completely as possible. Preferably, however, a calcium phosphate is used which is so little porous that there is no need to fill the pores.
Zur Vermeidung von Infektionen des Implantatlagers, die auch durch sorgfältig aseptisches Arbeiten nicht immer verhindert werden können, kann dem erfindungsgemäßen Implantationsmaterial auch ein Antibiotikum beigemischt werden. Insbesondere ist eine Beimischung von Gentamycin bevorzugt, mit dem sehr gute Ergebnisse erzielt werden. Die Verwendung von Gentamycin in Knochenzementen ist an sich u.a. durch die DOS 20 22 117 bekannt. Trotzdem war es nicht naheliegend, dem erfindungsgemäßen, caiciumphosphathaltigen Knochenzement Gentamycin beizumischen. Aus der Antibiotika-Fibel, 4. Auflage (1975), S. 373 unten bis 374 oben war nämlich bekannt, daß Gentamycin durch Calciumsalze, wie z.B. das Phosphat, in seiner Wirkung reduziert wird.To avoid infections of the implant site, which cannot always be prevented even by careful aseptic work, an antibiotic can also be added to the implant material according to the invention. In particular, an admixture of gentamycin is preferred, with which very good results are achieved. The use of gentamycin in bone cement is per se known by the DOS 20 22 117. Nevertheless, it was not obvious to add gentamicin to the bone cement according to the invention containing caicium phosphate. From the Antibiotics Guide, 4th edition (1975), p. 373 below to 374 above, it was known that gentamycin was caused by calcium salts, e.g. the effect of phosphate is reduced.
Überraschenderweise wurde jedoch gefunden, daß in die erfindungsgemäßen calciumphosphathaltigen Implantationsmaterialien sogar weniger Gentamycin eingearbeitet werden muß als in die bekannten Knochenzemente ohne Calciumphosphat, um einen gleich guten Schutz gegen Infektionen des Implantatlagers zu erreichen. Obwohl die Menge des zugesetzten Antibiotikums in weiten Bereichen variiert werden kann und damit ganz dem beabsichtigten Effekt angepaßt werden kann, liegen die in die erfindungsgemäßen Materialien einzuarbeitenden Mengen an Gentamycin zur Erzielung einer bestimmten Wirkung durchweg niedriger als die für bekannte Knochenzemente notwendigen Mengen.Surprisingly, however, it was found that even less gentamycin has to be incorporated into the calcium phosphate-containing implant materials according to the invention than into the known bone cements without calcium phosphate, in order to achieve equally good protection against infections of the implant site. Although the amount of the antibiotic added can be varied within wide limits and can thus be adapted entirely to the intended effect, the amounts of gentamycin to be incorporated into the materials according to the invention are consistently lower than the amounts required for known bone cements in order to achieve a certain effect.
Für Gentamycin haben sich bei bekannten Knochenzementen Zusätze von etwa 1 - 4 Gew.% als besonders günstig erwiesen. Da die Freisetzungsrate von Gentamycin aus dem erfindungsgemäßen Knochenzement überraschenderweise bis zu etwa zehnmal höher ist als aus den bekannten gentamycinhaltigen Knochenzementen liegt dieser besonders bevorzugte Bereich bei den erfindungsgemäßen Knochenzementen bei etwa 0,1 - 2 Gew.%. Geringere und auch höhere Zusätze von etwa 0,02 - 4 Gew.% können jedoch für spezielle Zwecke bevorzugt sein.Additions of about 1-4% by weight have proven to be particularly favorable for gentamycin in known bone cements. Since the release rate of gentamycin from the bone cement according to the invention is surprisingly up to about ten times higher than from the known gentamycin-containing bone cements, this particularly preferred range for the bone cements according to the invention is about 0.1-2% by weight. However, smaller and also higher additions of about 0.02-4% by weight can be preferred for special purposes.
Falls dem erfindungsgemäßen Material ein Antibiotikum beigemischt werden soll, können auch weitere Stoffe, wie z.B. die aus den DOS 26 51 441 und 27 27 535 bekannten Aminosäuren, zugesetzt werden, durch die eine besonders gleichmäßige Freisetzung des Antibiotikums erreicht wird. Anstelle von Gentamycin können natürlich auch andere Antibiotika eingesetzt werden. In Betracht kommen grundsätzlich alle Antibiotika, die durch die bei der Polymerisation auftretenden Temperaturen nicht geschädigt werden, gegenüber den verwendeten Kunststoffen stabil sind und die in der erwünschten Weise aus dem Kunststoff freigesetzt werden. Aus der Vielzahl der in Frage kommenden Antibiotika seien nur beispielsweise die folgenden genannt: Erythromycin, Lincomycin, Clindamycin, Novobiocin, Vancomycin, Fusidinsäure, Rifampicin, Polymycine, Neomycin, Kanamycin und Tobramycin.If an antibiotic is to be added to the material according to the invention, other substances, such as e.g. the amino acids known from DOS 26 51 441 and 27 27 535 are added, by means of which a particularly uniform release of the antibiotic is achieved. Other antibiotics can of course also be used instead of gentamycin. In principle, all antibiotics are considered which are not damaged by the temperatures occurring during the polymerization, are stable with respect to the plastics used and are released from the plastics in the desired manner. Of the large number of antibiotics in question, only the following are mentioned: erythromycin, lincomycin, clindamycin, novobiocin, vancomycin, fusidic acid, rifampicin, polymycine, neomycin, kanamycin and tobramycin.
Das Mischen der Komponenten kann an sich in jedem geeigneten Behältnis erfolgen, z.B. einer Schale oder einem Becher. Es sind dazu auch schon spezielle Mischeinrichtungen vorgeschlagen worden. Wegen der Anwesenheit des relativ schweren Calciumphosphats muß das Mischen besonders sorgfältig erfolgen, um eine homogene Verteilung des Calciumphosphats im Implantat zu erreichen. Dabei besteht im besonderen Maße die Gefahr, daß Luft mit in die Masse eingerührt wird, die insbesondere in Form von Luftbläschen dann auch in dem ausgehärteten Implantat zugegen ist und dessen Stabilität mindern kann. Insbesondere auch wegen der schlechten Benetzbarkeit der Calciumphosphatoberfläche durch das flüssige Monomere lagern sich an den Calciumphosphatteilchen bevorzugt Luftbläschen an, die den Kontakt Calciumphosphat/Zement verhindern und dadurch die Stabilität des ausgehärteten Implantats beträchtlich mindern. Die Untersuchung der herkömmlichen Knochenzemente hat außerdem gezeigt, daß als Folge von Fließeffekten um die Polymerkügelchen ebenfalls Luftblasen entstehen, die in der Regel zwischen 50 und 200 µm messen. Dieser Volumenanteil an eingeschlossenen Luftblasen kann im fertigen Zement bis zu 15 Volumenprozent ausmachen.The mixing of the components can be done in any suitable container, e.g. a bowl or a mug. Special mixing devices have also been proposed for this purpose. Because of the presence of the relatively heavy calcium phosphate, the mixing must be carried out with particular care in order to achieve a homogeneous distribution of the calcium phosphate in the implant. There is a particular risk of air being stirred into the mass, which is then present in the hardened implant, in particular in the form of air bubbles, and which can reduce its stability. In particular also because of the poor wettability of the calcium phosphate surface by the liquid monomer, air bubbles preferentially accumulate on the calcium phosphate particles, which prevent the calcium phosphate / cement contact and thereby considerably reduce the stability of the hardened implant. The examination of the conventional bone cements has also shown that air bubbles also arise as a result of flow effects around the polymer beads, which usually measure between 50 and 200 μm. This volume fraction of trapped air bubbles can make up to 15 volume percent in the finished cement.
Diese Einschlüsse von Luftbläschen, die sowohl bei den erfindungsgemäßen Implantaten unter Zusatz von Calciumphosphat als auch bei den Implantaten nach dem Stand der Technik zu beobachten sind, lassen sich überraschenderweise durch eine relativ einfach durchzuführende Verfahrensmaßnahme zumindest so weit vermindern, daß die Stabilität der Implantate beträchtlich erhöht wird. Es hat sich nämlich gezeigt, daß eine Komprimierung der Mischung aus Tricalciumphosphat, Präpolymerem und Monomerem, oder auch nur von Präpolymerem und Monomerem in einer bestimmten Phase der Polymerisation die Bildung von Lufteinschlüssen weitgehend verhindert. Diese Komprimierung erfolgt im ersten Abschnitt der Verarbeitungsphase der Knochenzemente und schließt sich unmittelbar dem Mischen von Präpolymerem und Monomerem, bzw. Tricalciumphosphat, Präpolymerem und Monomerem an.These inclusions of air bubbles, which can be observed both in the implants according to the invention with the addition of calcium phosphate and in the implants according to the prior art, can surprisingly be reduced at least to a sufficient extent by a relatively simple procedure that the stability of the implants increases considerably becomes. It has been shown that compression of the mixture of tricalcium phosphate, prepolymer and mono merem, or even only of prepolymer and monomer in a certain phase of the polymerization largely prevents the formation of air pockets. This compression takes place in the first section of the processing phase of the bone cements and immediately follows the mixing of prepolymer and monomer, or tricalcium phosphate, prepolymer and monomer.
Implantationsmaterialien, die so eingestellt sind, daß. sie nach etwa 6 - 15 Minuten nach dem Mischen ausge-härtet sind und-etwa bis zur 2. bis 8. Minute verarbeitbar sind, werden vorzugsweise in der Zeit zwischen der 1. und 4. Minute einem erhöhten Druck ausgesetzt.Implantation materials that are set so that. after about 6 - are hardened e-15 minutes after mixing of g and-up to approximately 2 to 8 minutes can be processed, are preferably subjected to an increased pressure in the time 1 to 4 minutes.
Dies geschieht vorzugsweise so, daß man die Mischung aus Tricalciumphosphat, Präpolymerem und Monomerem in einer Kolbenspritze passender Größe komprimiert, die mit Entlüftungslöchern versehen ist, deren Weite zwar nicht das Druchtreten der viskosen Mischung erlaubt, wohl aber das von eingeschlossener Luft und wobei der Spritzenstempel nicht luftdicht gegen die Spritzenwand abgeschlossen ist. Die hierfür notwendigen Drucke können durch ein Innengewinde der Spritze bei mäßigem Kraftaufwand erreicht werden, so daß es z.B. auch weiblichen Hilfspersonen ohne weiteres möglich ist, die erfindungsgemäßen Drucke zwischen 10 und 45 kp/cm2, vorzugsweise zwischen 20 und 40 kp/cm2 zu erzeugen. Der Druck wird für einige Zeit aufrechterhalten, vorzugsweise für etwa 1 - 2 Minuten. Danach kann das Implantationsmaterial nach Entfernen der als Entlüftungsloch dienenden engen Auslaßkanüle durch einen ausreichend weiten Auslaßkanal aus der Spritze herausgepreßt und in den Körper eingebracht werden.This is preferably done by compressing the mixture of tricalcium phosphate, prepolymer and monomer in a plunger syringe of the appropriate size, which is provided with ventilation holes, the width of which does not allow the viscous mixture to pass through, but does not allow trapped air and the syringe plunger does not is sealed airtight against the syringe wall. The pressures required for this can be achieved by an internal thread of the syringe with moderate effort, so that, for example, female assistants can easily increase the pressures according to the invention between 10 and 45 kp / cm 2 , preferably between 20 and 40 kp / cm 2 produce. The pressure is maintained for some time, preferably for about 1-2 minutes. After removal of the narrow outlet cannula serving as a vent hole, the implantation material can then be pressed out of the syringe through a sufficiently wide outlet channel and introduced into the body.
Implantationsmaterialien mit oder ohne Calciumphosphat, die unter Vorkomprimierung hergestellt sind, weisen einen sehr stark verringerten Anteil an Lufteinschlüssen auf, wobei diese wenigen Einschlüsse nur einen sehr geringen Durchmesser besitzen. Bei den Implantationsmaterialien, die Calciumphosphat enthalten, ist auffällig daß bei Proben, die unter Vorkomprimierung hergestellt sind, ein fester Verbund des Polymeren mit dem Calciumphosphat vorliegt, der nicht durch Lufteinschlüsse an der Calciumphsophatoberfläche gestört ist. Materialien, die unter Vorkomprimierung hergestellt sind, weisen daher eine erheblich größere Festigkeit auf als solche, die nach dem Mischen direkt in den Körper eingebracht sind. Die Verarbeitung der erfindungsgemäßen Materialien unter Vorkomprimierung ist daher ein weiterer wesentlicher Aspekt der vorliegenden Erfindung. Ein bescnderer Vorteil der erfindungsgemäßen Knochenzemente ist auch die Tatsache, daß auf die Zumischung eines Röntgenhontrastmittels verzichtet werden kann. Als solches wird den üblichen Knochenzementen in der Regel Bariumsulfat zugemischt, das jedoch aufgrund seiner Toxizität relativ große Probleme aufwirft. Das in den erfindungsgemäßen Knochenzementen enthaltene Calciumphosphat bietet jedcch eine ausreichend starke Röntgenabsorption, so daß kein zusätzliches Röntgenkontrastmittel beigemischt werden muß.Implant materials with or without calcium phosphate, which are produced under pre-compression a very greatly reduced proportion of air inclusions, these few inclusions only having a very small diameter. In the case of the implant materials which contain calcium phosphate, it is striking that in samples which are produced under pre-compression, there is a firm bond between the polymer and the calcium phosphate, which is not disturbed by air pockets on the calcium sulfate surface. Materials that are produced under pre-compression therefore have a considerably greater strength than those that are introduced directly into the body after mixing. Processing the materials according to the invention with pre-compression is therefore a further essential aspect of the present invention. Another advantage of the bone cements according to the invention is the fact that the addition of an X-ray contrast agent can be dispensed with. As such, barium sulfate is usually added to the usual bone cements, but this poses relatively large problems due to its toxicity. The calcium phosphate contained in the bone cements according to the invention, however, offers a sufficiently strong X-ray absorption so that no additional X-ray contrast agent has to be added.
Die erfindungsgemäßen Implantationsmaterialien, insbesondere solche, die nach dem erfindungsgemäßen Verfahren auch unter Vorkomprimierung hergestellt sind, können sehr vorteilhaft bei der Bekämpfung von Knochendefekten verwendet werden. Sie dienen dabei einmal zur Implantation von Endoprothesen, zum anderen aber auch zur Durchführung von sogenannten Verbundosteosynthesen, und zur Auffüllung von bestimmten Knochendefekten.The implantation materials according to the invention, in particular those which are also produced with pre-compression according to the method according to the invention, can be used very advantageously in combating bone defects. They are used for the implantation of endoprostheses on the one hand, but also for performing so-called composite osteosynthesis and for filling up certain bone defects.
Nachfolgend wird an Hand von Beispielen die Erfindung näher erläutert.The invention is explained in more detail below with the aid of examples.
40 g eines gefällten Tricalciumphosphats der chemischen Zusammensetzung Ca5(PO4)3OH mit einem Porenvolumen von 0,4 ml/g werden mit 20 ml Glycerin in 50 ml absolutem Alkohol versetzt und in einem Exsikkator 24 Stunden zur Entfernung des Alkohols stehengelassen. 5 g dieses vorbehandelten Tricalciumphosphats, das eine mittlere Teilchengröße zwischen 100 und 200 /um aufweist, werden mit 5,5 ml Methacrylsäuremethylester, enthaltend 0,7 % Di-methyl-p-toluidin und etwa 0,006 % Hydrochinon (im folgenden "Monomer" genannt) und 10,0 g eines feinteiligen (Teilchendurchmesser <30 µm) Copolymerisats von Acryl-und Methacrylsäuremethylester, enthaltend 0,5 % Dibenzoylperoxid und Spuren Chlorophyll (im folgenden "Polymer" genannt) gut gemischt.40 g of a precipitated tricalcium phosphate with the chemical composition Ca 5 (PO 4 ) 3 OH with a pore volume of 0.4 ml / g are mixed with 20 ml glycerol in 50 ml absolute alcohol and left in a desiccator for 24 hours to remove the alcohol. 5 g of this pretreated tricalcium phosphate having a mean particle size between 100 and 200 / um which are with 5.5 ml of methyl methacrylate containing 0.7% di-methyl-p-toluidine and about 0.006% of hydroquinone (hereinafter "monomer" mentioned ) and 10.0 g of a finely divided (particle diameter <30 μm) copolymer of methyl acrylate and methacrylic acid, containing 0.5% dibenzoyl peroxide and traces of chlorophyll (hereinafter referred to as "polymer").
Die Masse wird von der 1. bis zur 3. Minute nach dem Mischen unter einem Druck von etwa 35 kp/cm2 komprimiert und ist innerhalb der ersten 3 bis 6 Minuten verarbeitbar, bis etwa zur 8. Minute noch plastisch verformbar und nach etwa 10 - 11 Minuten fest. Der erhaltene Zement ist gut hart und zeigt keine Reste von Glycerin an der Oberfläche. Ähnlich gute Resultate werden bei Verwendung von 7 ml und insbesondere bei Verwendung von 6 ml Monomer erhalten.The mass is compressed from the 1st to the 3rd minute after mixing under a pressure of about 35 kp / cm 2 and can be processed within the first 3 to 6 minutes, can be plastically deformed until about the 8th minute and after about 10 - 11 minutes fixed. The cement obtained is very hard and shows no residues of glycerol on the surface. Similar good results are obtained when using 7 ml and especially when using 6 ml of monomer.
40 g des gefällten Tricalciumphosphats von Beispiel 1 werden mit 30 ml Glycerin in 40 ml absolutem Alkohol versetzt und 24 Stunden in einem Exsikkator zur Entfernung des Alkohols stehen gelassen. 5 g dieses so behandelten Tricalciumphosphats werden mit 6 ml Monomer und 10 g Polymer gut gemischt. Die Masse läßt sich sehr gut mischen und ist von der 2. bis zur 9. Minute spritzbar, bis zur 11. Minute von Hand knetbar, nach etwa 12 Minuten warm und nach etwa 13 Minuten erhärtet. Der erhaltende Zement ist sehr schön hart und die Oberfläche ist frei von Glycerinresten. Eine Komprimierung auf einen Druck von etwa 35 kp/cm2 erfolgt zwischen der 1 und 3. Minute.40 g of the precipitated tricalcium phosphate from Example 1 are mixed with 30 ml of glycerol in 40 ml of absolute alcohol and left to stand in a desiccator for 24 hours to remove the alcohol. 5 g of this tricalcium phosphate treated in this way are mixed well with 6 ml of monomer and 10 g of polymer. The mass can be very mix well and is sprayable from the 2nd to the 9th minute, kneadable by hand until the 11th minute, warm after about 12 minutes and hardened after about 13 minutes. The cement obtained is very hard and the surface is free of glycerine residues. Compression to a pressure of about 35 kp / cm 2 takes place between the 1st and 3rd minute.
Die folgenden Ausgangsmaterialien
- A ein gefälltes Tricalciumphosphat mit einem Porenvolumen von 0,35 ml/g (E. Merck, Art.Nr. 2143)
- B ein gefälltes Tricalciumphosphat mit einem Porenvolumen von 0,40 ml/g
- C eine innige Mischung aus 2 Teilen Calciumhydrogenphosphat und einem Teil Calciumcarbonat
- A a precipitated tricalcium phosphate with a pore volume of 0.35 ml / g (E. Merck, Art.No. 2143)
- B a precipitated tricalcium phosphate with a pore volume of 0.40 ml / g
- C an intimate mixture of 2 parts of calcium hydrogen phosphate and one part of calcium carbonate
Die Ausgangsmaterialien A und B werden danach jeweils 1 Stunde bei 600 °, 900 °, 1200° und 1500 °C geglüht und Ausgangsmaterial C zunächst 3 Stunden bei 1200 ° ge-glüht, danach grob zerteilt, nochmals zu Tabletten verpreßt und für eine Stunde bei 1500 °C geglüht.The starting materials A and B are then annealed at 600 °, 900 °, 1200 ° and 1500 ° C for 1 hour each and starting material C is first annealed at 1200 ° g for 3 hours, then roughly divided, compressed again into tablets and for one hour annealed at 1500 ° C.
In der folgenden Tabelle sind die spezifischen Oberflächen und spezifischen Porenvolumina der so behandelten Ausgangsmaterialien dargestellt.
Eine kristallographische Untersuchung der Materialien zeigt, daß A und B bei allen Glühtemperaturen eine Hydroxylapatit-Struktur besitzen, während C eine Whitlockit-Struktur besitzt.Crystallographic examination of the materials shows that A and B have a hydroxyapatite structure at all annealing temperatures, while C has a whitlockite structure.
Die geglühten Materialien können durch Zerkleinern und Klassieren in allen gewünschten Teilchengrößen gewonnen werden.The annealed materials can be obtained by crushing and classifying them in all desired particle sizes.
5 g des bei 1200 °C geglühten Tricalciumphosphats A nach Beispiel 3a mit einer Teilchengröße zwischen 63 und 200 µm werden mit 6 ml Monomer und 10 g Polymer gut gemischt. Von etwa der 1. bis etwa zur 3. Minute wird die Mischung unter einem Druck von etwa 35 kp/cm2 komprimiert. Die Masse ist bis zur 5. Minute spritzbar, bis zur 8. Minute von Hand knetbar und plastisch deformierbar, nach etwa 9 Minuten warm und nach etwa 10 Minuten erhärtet. Der erhaltene Knochenzement ist gut hart.5 g of the tricalcium phosphate A annealed at 1200 ° C. according to Example 3a with a particle size between 63 and 200 μm are mixed well with 6 ml of monomer and 10 g of polymer. From about the 1st to about the 3rd minute, the mixture is compressed under a pressure of about 35 kp / cm 2 . The mass can be sprayed up to the 5th minute, kneadable and plastically deformable by the 8th minute, warm after about 9 minutes and hardened after about 10 minutes. The bone cement obtained is very hard.
In gleicher Weise und mit gleich guten Ergebnissen können auch die bei 1200 - 1500 °C geglühten Materialien B und C verwendet werden.Materials B and C annealed at 1200 - 1500 ° C can be used in the same way and with equally good results.
20 g des bei 1200°C geglühten Tricalciumphospnats A nach Beispiel 3a mit einer Teilchengröße zwischen 50 und 300 µm werden mit 24 ml Monomer und 40 g Polymer gut gemischt. Von etwa der 1. bis zur 3. Minute wird die Mischung unter einem Druck von etwa 35 kp/cm2 in einer Kolbenspritze komprimiert.20 g of the tricalcium phosphate A annealed at 1200 ° C. according to Example 3a with a particle size between 50 and 300 μm are mixed well with 24 ml of monomer and 40 g of polymer. From about the 1st to the 3rd minute, the mixture is compressed under a pressure of about 35 kp / cm 2 in a piston syringe.
Ein arthrotisch verändertes Hüftgelenk wird eröffnet, der Schenkelhals freipräpariert, die Kapsel entfernt und der Hüftkopf mit dem Schenkelhals 1 cm oberhalb des Trochanter minors in einem Winkel zur Horizontalebene von 35 - 45 Grad rese-ziert, die Markhöhle kurettiert und mit einer Spezialfräse aufbereitet, so daß eine künstliche Metallprothese eingepaßt werden kann . In die so vorbereitete Femurmarkhöhle wird ein Entlüftungsschlauch eingeführt, der bis unterhalb die Prothesenspitze reicht.An arthrotically modified hip joint is opened, the femoral neck is dissected, the capsule is removed, and the femoral head with the femoral neck is resected 1 cm above the trochanter minor at an angle to the horizontal plane of 35 - 45 degrees, the medullary cavity is curetted and prepared with a special milling machine that an artificial metal prosthesis can be fitted. A ventilation tube is inserted into the femoral marrow cavity prepared in this way, which extends to below the tip of the prosthesis.
In die ausgespülte und in dieser Weise präparierte Markhöhle wird nun die in der oben beschriebenen Weise zubereitete Knochenzementmasse injiziert und anschließend die Metallschaftprothese so eingeführt, daß der Metallschaft vollständig von Knochenzement umgeben ist und diesen Kunststoffköcher nirgends perforierte Dies wird dadurch erreicht, daß Implantationswinkel und Resektionsflächen durch praeoperative Zeichnungen geplant sind, wodurch die Stelle des Eintauchens der Metallprothese in den plastischen Zement vorher bestimmt werden kann. In dieser Position wird die implantierte Metallprothese unverrückbar bis zur elften Minute unter Druck eingepreßt gehalten. Nach dieser Zeit ist der knochenzement ausgehärtet und die Prothese stabil implantiert.The bone cement mass prepared in the manner described above is then injected into the rinsed and prepared medullary cavity and then the metal shaft prosthesis is inserted so that the metal shaft is completely surrounded by bone cement and this plastic tube is nowhere perforated.This is achieved by implantation angles and resection surfaces preparatory drawings are planned, whereby the location of the immersion of the metal prosthesis in the plastic cement can be determined beforehand. In this position, the implanted metal prosthesis becomes immovable until the eleventh minute under pressure pressed in. After this time, the bone cement has hardened and the prosthesis is stably implanted.
Die in der Grenzzone auftretenden Schrumpfungsspalten sind so klein, daß bei normaler Knochenvaskularisation der Spalt nach spätestens 12 Wochen knöchern aufgefüllt wird, so daß die künstliche Prothese von diesem Zeitpunkt an voll belastet werden kann.The shrinkage gaps occurring in the border zone are so small that with normal bone vascularization the gap is filled up to the bone after no more than 12 weeks, so that the artificial prosthesis can be fully loaded from this point on.
Ein arthrotischer, aber in seiner äußeren Form noch gut erhaltener Hüftkopf kann auch für eine sogenannte Kappenprothese vorbereitet werden. Eierfür wird der Hüftkopf von seinem Restknorpel befreit. Die Knorpelgrundplatte wird mit einer Spezialfräse aufbereiten, so daß blutende Knochenpunkte sichtbar werden. Die Hüftkappe wird in der Weise.angepaßt, daß die Grenzzone Knochen und Zement in erster Linie auf Druckkräfte beansprucht wird, d. h. entgegen der physiologischen Winkelstellung des Hüftkopfes wird die Kappe valgisiert und deflektiert auf den Hüftkopf aufgebracht.An arthrotic femoral head that is still well preserved in its outer shape can also be prepared for a so-called cap prosthesis. The femoral head is freed of its residual cartilage. The cartilage base plate is prepared with a special milling machine so that bleeding bone points become visible. The hip cap is adapted in such a way that the bone and cement border zone is primarily subjected to compressive forces, i. H. contrary to the physiological angular position of the femoral head, the cap is valgized and deflected onto the femoral head.
Anschließend wird der Hüftkopf getrocknet und die Kappenprothese mit einer 2 mm dicken Schicht eines Zementes belegt, der in der im Beispiel 4 beschriebenen Weise zubereitet worden ist. Die den Zement enthaltende Kappe wird nun über den gut trocknen Hüftkopf gestülpt und fest angepreßt. Der dabei hervorquellende Zement wird entfernt und die Kappe bis zur elften Minute in der sorgfältig geplanten Position angepreßt gehalten. Die so fixierte Metallkappe zeigt sofort einen ausreichend stabilen Sitz, so daß der überkappte Femurkopf ohne Schwierigkeiten in die ins Becken implantierte Kunststoffpfanne reponiert werden kann.The femoral head is then dried and the cap prosthesis is coated with a 2 mm thick layer of cement which has been prepared in the manner described in Example 4. The cap containing the cement is now put over the well-dried femoral head and pressed firmly. The cement that swells out is removed and the cap is held in the carefully planned position until the eleventh minute. The metal cap fixed in this way immediately shows a sufficiently stable fit so that the capped femoral head can be repositioned without difficulty into the plastic socket implanted in the pelvis.
In Fällen von Knochenfrakturen, insbesondere von sogenannten pathologischen Frakturen bei Knochentumoren oder Knochenmetastasen anderer Primärtumoren kann eine Verbundosteosynthese zur Anwendung kommen. Hierbei werden zwei Fragmente, in denen Metallschrauben nicht mehr sicher fixiert werden können in der Weise mit einem Knochenzement, der nach Beispiel 4 zubereitet worden ist, vom Markraum her ausgefüllt, daß entweder direkt in den weichen Zement oder nach Bohren und Gewindeschneiden des ausgehärteten Zementes, auf diesen Verbund von Knochen und Knochenzement, eine Metallplatte mit Schrauben fixiert werden kann.In cases of bone fractures, especially so-called pathological fractures in bone tumors or bone metastases from other primary tumors, composite osteosynthesis can be used. Two fragments in which metal screws can no longer be securely fixed are filled in from the medullary cavity with a bone cement that has been prepared according to Example 4, either directly in the soft cement or after drilling and threading the hardened cement, on this bond of bone and bone cement, a metal plate can be fixed with screws.
Eine solche Verbundosteosynthese kann auch ausgeführt werden, indem der Verbund von Zement und Knochen durch einen intramedullären Metallnagel verstärkt wird, der die Fragmente gleichsam auffädelt. Nach Aushärten des Zementes bekommen die Schrauben, bzw. die Metallimplantate einen festen Halt, so daß es zur schnellen Knochenheilung kommen kann. Es konnte gezeigt werden, daß die Knochenheilung durch die Zementplombierung nicht gestört wird.Such a composite osteosynthesis can also be carried out by strengthening the bond between cement and bone by means of an intramedullary metal nail, which thread the fragments as it were. After the cement has hardened, the screws or the metal implants have a firm hold so that the bone can heal quickly. It could be shown that the cement healing does not interfere with bone healing.
In gewissen Fällen, in denen epiphysennah Knochentumore aufgetreten sind, können große knöcherne Defekte, bei denen eine Auffüllung durch körpereigene Knochen nicht mehr zu erwarten ist und auf Grund derer eine Belastbarkeit der Extremität nicht mehr gewährleistet ist, mit Knochenzementen aufgefüllt und die Extremitäten mit oder ohne Metallarmierung mit dem nach Beispiel 4 aufbereiteten Knochenzement, aufgefüllt werden. Die so behandelten Knochen erreichen wieder eine Belastungsstabilität oder zumindest eine Übungsstabilität, die zu einer erheblichen Pflegeerleichterung beiträgt.In certain cases in which bone tumors close to the epiphyses have occurred, large bony defects, in which filling by the body's own bones is no longer to be expected and due to which the resilience of the extremity can no longer be guaranteed, can be filled with bone cement and the extremities with or without Metal reinforcement are filled with the bone cement prepared according to Example 4. The bones treated in this way again achieve a load stability or at least exercise stability which contributes to a considerable ease of care.
Die Beispiele 1 - 3 werden wiederholt, wobei anstelle des dort verwendeten feinteiligen Präpolymeren ein Polymergranulat mit einer Teilchengröße von 40 - 60 µm verwendet wird.Examples 1-3 are repeated, using instead of the finely divided prepolymer used there a polymer granulate with a particle size of 40-60 μm.
Die Beispiele 1 - 3 werden wiederholt, wobei anstelle des dort verwendeten feinteiligen Präpolymeren fadenförmige Polymerzylinder mit einer Länge von 0,5 bis 1 mm und einem Durchmesser von etwa 50 um verwendet werden.Examples 1-3 are repeated, using filament-shaped polymer cylinders with a length of 0.5 to 1 mm and a diameter of about 50 .mu.m instead of the finely divided prepolymer used there.
Aus 30 g Polymer, 21 ml Monomer, 15 g Tricalciumphosphat und 0,5 g Gentamycin-Base wird eine Knochenzementmischung bereitet, aus der zylinderförmige Prüfkörper mit einem Durchmesser von 25 mm und einer Höhe von 10 mm geformt werden. Ein solcher Prüfkörper wird in 20 ml Phosphatpuffer von pH 7,4 eingebracht. Nachjeweils 24 Stunden wird die Flüssigkeit gewechselt und auf ihren Gentamycingehalt untersucht. Als Vergleich dient ein analoger Prüfkörper, der aus einer Mischung von 40 g Polymer, 20 ml Monomer und 0,5 g Gentamycin-Base geformt wurde.A bone cement mixture is prepared from 30 g polymer, 21 ml monomer, 15 g tricalcium phosphate and 0.5 g gentamycin base, from which cylindrical test specimens with a diameter of 25 mm and a height of 10 mm are formed. Such a test specimen is placed in 20 ml of pH 7.4 phosphate buffer. The fluid is changed every 24 hours and examined for its gentamycin content. An analog test piece, which was formed from a mixture of 40 g of polymer, 20 ml of monomer and 0.5 g of gentamycin base, serves as a comparison.
Der Vergleich brachte das folgende Ergebnis:
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT80100293T ATE9866T1 (en) | 1979-02-16 | 1980-01-22 | BONE CEMENT AND PROCESS FOR ITS PRODUCTION. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19792905878 DE2905878A1 (en) | 1979-02-16 | 1979-02-16 | IMPLANTATION MATERIALS AND METHOD FOR THEIR PRODUCTION |
DE2905878 | 1979-02-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0016906A1 true EP0016906A1 (en) | 1980-10-15 |
EP0016906B1 EP0016906B1 (en) | 1984-10-17 |
Family
ID=6063045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP80100293A Expired EP0016906B1 (en) | 1979-02-16 | 1980-01-22 | Bone cement and method for its production |
Country Status (6)
Country | Link |
---|---|
US (1) | US4373217A (en) |
EP (1) | EP0016906B1 (en) |
AT (1) | ATE9866T1 (en) |
CA (1) | CA1162851A (en) |
DE (2) | DE2905878A1 (en) |
ES (1) | ES8201181A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0087662A1 (en) * | 1982-02-25 | 1983-09-07 | MERCK PATENT GmbH | Pharmaceuticals deposition system |
GB2139095A (en) * | 1983-05-07 | 1984-11-07 | Friedrichsfeld Gmbh | Improvements in and relating to semi-implants |
EP0131291A1 (en) * | 1983-07-12 | 1985-01-16 | MERCK PATENT GmbH | Materials for implantation |
EP0159036A2 (en) * | 1984-04-19 | 1985-10-23 | Draenert, Klaus, Dr.med.Dr.med.habil. | Anchoring means with coating for implants |
EP0164483A1 (en) * | 1984-06-12 | 1985-12-18 | Oscobal Ag | Method of producing a bone replacement material |
WO1986001726A1 (en) * | 1984-09-10 | 1986-03-27 | MERCK Patent Gesellschaft mit beschränkter Haftung | Material containing carbonate apatite and use of carbonate apatite for implants |
DE3445731A1 (en) * | 1984-12-14 | 1986-06-19 | Klaus Dr.med. Dr.med.habil. 8000 München Draenert | Material and use thereof |
WO1986003667A1 (en) * | 1984-12-14 | 1986-07-03 | Klaus Draenert | Occlusion device made of surgical material |
EP0202445A2 (en) * | 1985-04-18 | 1986-11-26 | MERCK PATENT GmbH | Pharmaceutical deposition forms containing antitumour agents |
EP0242672A2 (en) * | 1986-04-18 | 1987-10-28 | MERCK PATENT GmbH | Tricalcium phosphate for use as implants |
EP0425200A1 (en) * | 1989-10-19 | 1991-05-02 | Nobuo Nakabayashi | Bone cement composition, cured product thereof, implant material and process for the preparation of the same |
WO1992006717A1 (en) * | 1990-10-19 | 1992-04-30 | Klaus Draenert | Starting material for the production of bone cement, process for producing the same and process for producing bone cement |
EP0705609A2 (en) | 1994-10-06 | 1996-04-10 | MERCK PATENT GmbH | Porous bone-replacing material |
US5522894A (en) * | 1984-12-14 | 1996-06-04 | Draenert; Klaus | Bone replacement material made of absorbable beads |
DE102005023094A1 (en) * | 2005-05-13 | 2006-11-16 | Nies, Berthold, Dr. | Bioactive bone cement e.g. for implantation into bones, made by adding small amounts of polymerizable monomers containing anionic groups which cause cement surface to mineralize after being incubated in simulated body fluid |
CN101961506A (en) * | 2010-09-30 | 2011-02-02 | 深圳市第二人民医院 | Composite nano biological bone glue with osteogenesis inducing activity and preparation method thereof |
Families Citing this family (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4927361A (en) * | 1982-07-27 | 1990-05-22 | Smith Dennis C | Orthodontic attachments |
DE3245956A1 (en) * | 1982-12-11 | 1984-06-14 | Beiersdorf Ag, 2000 Hamburg | SURGICAL MATERIAL |
DE3314977A1 (en) * | 1983-04-26 | 1984-10-31 | ESPE Fabrik pharmazeutischer Präparate GmbH, 8031 Seefeld | USE OF DIFUNCTIONAL ACRYLIC ACID AND METHACRYLIC ACID ESTERS FOR THE PRODUCTION OF CURABLE BONE CEMENTS |
US4654314A (en) * | 1983-07-09 | 1987-03-31 | Sumitomo Cement Co., Ltd. | Porous ceramic material and processes for preparing same |
GB8328074D0 (en) * | 1983-10-20 | 1983-11-23 | Geistlich Soehne Ag | Chemical compositions |
DE8420774U1 (en) * | 1984-07-11 | 1985-09-12 | Draenert, Klaus, Dr.Med. Dr.Med.Habil., 8000 Muenchen | Device for mixing and applying bone cement |
US4863475A (en) * | 1984-08-31 | 1989-09-05 | Zimmer, Inc. | Implant and method for production thereof |
WO1986001725A1 (en) * | 1984-09-10 | 1986-03-27 | Klaus Draenert | Bone cement and process for its manufacture |
JPS6168053A (en) * | 1984-09-10 | 1986-04-08 | クラウス・ドレナート | Bone cement |
US4722870A (en) * | 1985-01-22 | 1988-02-02 | Interpore International | Metal-ceramic composite material useful for implant devices |
US4842604A (en) * | 1985-02-19 | 1989-06-27 | The Dow Chemical Company | Composites of unsintered calcium phosphates and synthetic biodegradable polymers useful as hard tissue prosthetics |
US4661536A (en) * | 1985-02-19 | 1987-04-28 | The Dow Chemical Company | Process for the preparation of hard tissue prosthetics |
DE3671375D1 (en) * | 1985-02-19 | 1990-06-28 | Dow Chemical Co | HARD TISSUE PROSTHESIS AND METHOD FOR THEIR PRODUCTION. |
US5007930A (en) * | 1985-02-19 | 1991-04-16 | The Dow Chemical Company | Composites of unsintered calcium phosphates and synthetic biodegradable polymers useful as hard tissue prosthetics |
US4698375A (en) * | 1985-02-19 | 1987-10-06 | The Dow Chemical Company | Composites of unsintered calcium phosphates and synthetic biodegradable polymers useful as hard tissue prosthetics |
US4718910A (en) * | 1985-07-16 | 1988-01-12 | Klaus Draenert | Bone cement and process for preparing the same |
US4795475A (en) * | 1985-08-09 | 1989-01-03 | Walker Michael M | Prosthesis utilizing salt-forming oxyacids for bone fixation |
DE3533369A1 (en) * | 1985-09-19 | 1987-03-19 | Alois Prof Dr Med Bloemer | ANTIBIOTIC CONTAINER AND ITS USE AS SURGICAL PLASTIC MATERIAL |
US4699141A (en) * | 1986-01-16 | 1987-10-13 | Rhode Island Hospital | Neovascularization |
US4778834A (en) * | 1987-02-24 | 1988-10-18 | Sterling Drug Inc. | Hydroxylapatite-synthetic resin composites |
US5085861A (en) * | 1987-03-12 | 1992-02-04 | The Beth Israel Hospital Association | Bioerodable implant composition comprising crosslinked biodegradable polyesters |
US4843112A (en) * | 1987-03-12 | 1989-06-27 | The Beth Israel Hospital Association | Bioerodable implant composition |
US5106614A (en) * | 1987-07-30 | 1992-04-21 | Pfizer Hospital Products Group, Inc. | Bone cement for sustained release of substances |
US4900546A (en) * | 1987-07-30 | 1990-02-13 | Pfizer Hospital Products Group, Inc. | Bone cement for sustained release of substances |
DE3728686A1 (en) * | 1987-08-27 | 1989-03-09 | Draenert Klaus | PREDICTABLE SURGICAL NETWORK |
US7452359B1 (en) | 1988-06-13 | 2008-11-18 | Warsaw Orthopedic, Inc. | Apparatus for inserting spinal implants |
US4863974A (en) * | 1988-08-03 | 1989-09-05 | W. L. Gore & Associates, Inc. | Bone growth matrix and process for making it |
JPH085712B2 (en) * | 1988-09-15 | 1996-01-24 | 旭光学工業株式会社 | Oriented calcium phosphate compound moldings and sintered bodies, and methods for producing the same |
DE3903695A1 (en) * | 1989-02-08 | 1990-08-09 | Merck Patent Gmbh | RESORBABLE BONE CERAMICS BASED ON TRICALCIUMPHOSPHATE |
US5147403A (en) * | 1989-03-15 | 1992-09-15 | United States Gypsum Company | Prosthesis implantation method |
US5037437B1 (en) * | 1990-01-18 | 1998-04-14 | Univ Washington | Method of bone preparation for prosthetic fixation |
US5266248A (en) * | 1990-05-10 | 1993-11-30 | Torao Ohtsuka | Method of producing hydroxylapatite base porous beads filler for an organism |
JP2657847B2 (en) * | 1990-05-10 | 1997-09-30 | 寅雄 大塚 | Hydroxyapatite porous biofill material and method for producing the same |
ATE327782T1 (en) * | 1990-09-13 | 2006-06-15 | Klaus Draenert | MULTI-COMPONENT MATERIAL AND METHOD FOR PRODUCING IT |
US6080801A (en) * | 1990-09-13 | 2000-06-27 | Klaus Draenert | Multi-component material and process for its preparation |
DE4033291A1 (en) * | 1990-10-19 | 1992-04-23 | Draenert Klaus | MATERIAL AND METHOD FOR THE PRODUCTION THEREOF |
US5746200A (en) * | 1990-10-19 | 1998-05-05 | Draenert; Klaus | Trabecula nasal filter having both macropores and micropores |
US5993716A (en) * | 1990-10-19 | 1999-11-30 | Draenert; Klaus | Material and process for its preparation |
DE4033308A1 (en) * | 1990-10-19 | 1992-04-23 | Draenert Klaus | IMPLANT AND METHOD FOR THE PRODUCTION THEREOF |
US7968110B2 (en) * | 1992-02-11 | 2011-06-28 | Merz Aesthetics, Inc. | Tissue augmentation material and method |
US7060287B1 (en) * | 1992-02-11 | 2006-06-13 | Bioform Inc. | Tissue augmentation material and method |
US6537574B1 (en) * | 1992-02-11 | 2003-03-25 | Bioform, Inc. | Soft tissue augmentation material |
US5370698A (en) * | 1992-04-16 | 1994-12-06 | Clemson University | Isoelastic implants with improved anchorage means |
US5508342A (en) * | 1994-02-01 | 1996-04-16 | The United States Of America As Represented By The Secretary Of Commerce | Polymeric amorphous calcium phosphate compositions |
AU1287895A (en) | 1994-10-03 | 1996-04-26 | Otogen Corporation | Differentially biodegradable biomedical implants |
AU3795395A (en) * | 1994-11-30 | 1996-06-06 | Ethicon Inc. | Hard tissue bone cements and substitutes |
DE59610355D1 (en) * | 1995-12-18 | 2003-05-22 | Schug Jens | MEDICAL IMPLANT |
US5718717A (en) | 1996-08-19 | 1998-02-17 | Bonutti; Peter M. | Suture anchor |
US5847046A (en) * | 1997-03-12 | 1998-12-08 | United States Surgical Corporation | Biodegradable bone cement |
US5919473A (en) * | 1997-05-12 | 1999-07-06 | Elkhoury; George F. | Methods and devices for delivering opioid analgesics to wounds via a subdermal implant |
US6475230B1 (en) * | 1997-08-01 | 2002-11-05 | Peter M. Bonutti | Method and apparatus for securing a suture |
US5889075A (en) * | 1997-10-10 | 1999-03-30 | United States Surgical Corporation | Irradiated surgical suture and method for making same |
US6309420B1 (en) * | 1997-10-14 | 2001-10-30 | Parallax Medical, Inc. | Enhanced visibility materials for implantation in hard tissue |
US6045551A (en) | 1998-02-06 | 2000-04-04 | Bonutti; Peter M. | Bone suture |
US7572263B2 (en) * | 1998-04-01 | 2009-08-11 | Arthrocare Corporation | High pressure applicator |
AU3203599A (en) | 1998-04-01 | 1999-10-18 | Parallax Medical, Inc. | Pressure applicator for hard tissue implant placement |
US6110484A (en) * | 1998-11-24 | 2000-08-29 | Cohesion Technologies, Inc. | Collagen-polymer matrices with differential biodegradability |
WO2000056254A1 (en) | 1999-03-24 | 2000-09-28 | Parallax Medical, Inc. | Non-compliant system for delivery of implant material |
US6506217B1 (en) * | 1999-03-29 | 2003-01-14 | Arnett Facial Reconstruction Courses, Inc. | Moldable post-implantation bone filler and method |
US6689823B1 (en) | 1999-03-31 | 2004-02-10 | The Brigham And Women's Hospital, Inc. | Nanocomposite surgical materials and method of producing them |
US6368343B1 (en) | 2000-03-13 | 2002-04-09 | Peter M. Bonutti | Method of using ultrasonic vibration to secure body tissue |
US6447516B1 (en) | 1999-08-09 | 2002-09-10 | Peter M. Bonutti | Method of securing tissue |
US6783515B1 (en) | 1999-09-30 | 2004-08-31 | Arthrocare Corporation | High pressure delivery system |
US6635073B2 (en) | 2000-05-03 | 2003-10-21 | Peter M. Bonutti | Method of securing body tissue |
US20020045678A1 (en) * | 2000-08-22 | 2002-04-18 | Lopez Larry A. | Dental restorative compositions and method of use thereof |
US6786930B2 (en) * | 2000-12-04 | 2004-09-07 | Spineco, Inc. | Molded surgical implant and method |
US9080146B2 (en) * | 2001-01-11 | 2015-07-14 | Celonova Biosciences, Inc. | Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface |
ITMI20010089A1 (en) * | 2001-01-18 | 2002-07-18 | Consiglio Nazionale Ricerche | METHOD FOR OBTAINING A BICOMPATIBLE POLYMER / CERAMIC COMPOSITE MATERIAL WITH A PREDETERMINED POROSITY |
US7008433B2 (en) | 2001-02-15 | 2006-03-07 | Depuy Acromed, Inc. | Vertebroplasty injection device |
US6949251B2 (en) * | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
US20070191964A1 (en) * | 2001-04-04 | 2007-08-16 | Arthrocare Corporation | Enhanced visibility materials for implantation in hard tissue |
US6719765B2 (en) | 2001-12-03 | 2004-04-13 | Bonutti 2003 Trust-A | Magnetic suturing system and method |
US20050080425A1 (en) * | 2002-03-18 | 2005-04-14 | Mohit Bhatnagar | Minimally invasive bone manipulation device and method of use |
US20030220650A1 (en) * | 2002-03-18 | 2003-11-27 | Major Eric D. | Minimally invasive bone manipulation device and method of use |
CN1309360C (en) * | 2002-06-20 | 2007-04-11 | 多克萨股份公司 | System for a chemically bonded ceramic material, a powdered material and a hydration liquid therefore, the ceramic material, a method for its production and a device |
US20040002770A1 (en) * | 2002-06-28 | 2004-01-01 | King Richard S. | Polymer-bioceramic composite for orthopaedic applications and method of manufacture thereof |
US20080226723A1 (en) * | 2002-07-05 | 2008-09-18 | Celonova Biosciences, Inc. | Loadable Polymeric Particles for Therapeutic Use in Erectile Dysfunction and Methods of Preparing and Using the Same |
US7138442B2 (en) * | 2002-08-30 | 2006-11-21 | Biomet, Inc. | Reduced exothermic bone replacement cement |
FR2850282B1 (en) * | 2003-01-27 | 2007-04-06 | Jerome Asius | INJECTABLE IMPLANT BASED ON CERAMIC FOR THE FILLING OF WRINKLES, CUTANEOUS DEPRESSIONS AND SCARS, AND ITS PREPARATION |
US20060264967A1 (en) | 2003-03-14 | 2006-11-23 | Ferreyro Roque H | Hydraulic device for the injection of bone cement in percutaneous vertebroplasty |
US8066713B2 (en) | 2003-03-31 | 2011-11-29 | Depuy Spine, Inc. | Remotely-activated vertebroplasty injection device |
US20070032567A1 (en) * | 2003-06-17 | 2007-02-08 | Disc-O-Tech Medical | Bone Cement And Methods Of Use Thereof |
US8415407B2 (en) * | 2004-03-21 | 2013-04-09 | Depuy Spine, Inc. | Methods, materials, and apparatus for treating bone and other tissue |
US20040262809A1 (en) * | 2003-06-30 | 2004-12-30 | Smith Todd S. | Crosslinked polymeric composite for orthopaedic implants |
US20050015148A1 (en) * | 2003-07-18 | 2005-01-20 | Jansen Lex P. | Biocompatible wires and methods of using same to fill bone void |
US8529625B2 (en) | 2003-08-22 | 2013-09-10 | Smith & Nephew, Inc. | Tissue repair and replacement |
WO2005030034A2 (en) | 2003-09-26 | 2005-04-07 | Depuy Spine, Inc. | Device for delivering viscous material |
DE10355992A1 (en) * | 2003-11-27 | 2005-06-30 | Curasan Ag | Bioresorbable composite material |
WO2005072417A2 (en) * | 2004-01-27 | 2005-08-11 | The Ohio State University Research Foundation | Vascular endothelial growth factors and methods of their use |
US20060064101A1 (en) * | 2004-02-12 | 2006-03-23 | Arthrocare Corporation | Bone access system |
US7384430B2 (en) * | 2004-06-30 | 2008-06-10 | Depuy Products, Inc. | Low crystalline polymeric material for orthopaedic implants and an associated method |
EP1786343B1 (en) * | 2004-07-30 | 2012-05-02 | Depuy Spine, Inc. | Apparatus for treating bone and other tissue |
US9107850B2 (en) * | 2004-10-25 | 2015-08-18 | Celonova Biosciences, Inc. | Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
US9114162B2 (en) | 2004-10-25 | 2015-08-25 | Celonova Biosciences, Inc. | Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same |
BRPI0518383A2 (en) | 2004-10-25 | 2008-11-18 | Polyzenix Gmbh | Chargeable polymeric particles for therapeutical and / or diagnostic applications and methods for preparing and using them |
US20210299056A9 (en) | 2004-10-25 | 2021-09-30 | Varian Medical Systems, Inc. | Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods |
US7879275B2 (en) * | 2004-12-30 | 2011-02-01 | Depuy Products, Inc. | Orthopaedic bearing and method for making the same |
US7883653B2 (en) | 2004-12-30 | 2011-02-08 | Depuy Products, Inc. | Method of making an implantable orthopaedic bearing |
US7896921B2 (en) * | 2004-12-30 | 2011-03-01 | Depuy Products, Inc. | Orthopaedic bearing and method for making the same |
US20060164913A1 (en) * | 2005-01-21 | 2006-07-27 | Arthrocare Corporation | Multi-chamber integrated mixing and delivery system |
EP1893174A2 (en) * | 2005-05-10 | 2008-03-05 | Cytophil, Inc. | Injectable hydrogels and methods of making and using same |
DE102005033210B4 (en) * | 2005-06-22 | 2008-04-30 | Heraeus Kulzer Gmbh | Polymethylmethacrylate bone cement |
DE102005032110B3 (en) * | 2005-07-07 | 2006-08-17 | Heraeus Kulzer Gmbh | Colored polymethyl-methacrylate cement to anchor endoprostheses in orthopoedic surgery incorporates a mixture of one or more dyes |
US9381024B2 (en) * | 2005-07-31 | 2016-07-05 | DePuy Synthes Products, Inc. | Marked tools |
US9918767B2 (en) | 2005-08-01 | 2018-03-20 | DePuy Synthes Products, Inc. | Temperature control system |
DE102005040429A1 (en) * | 2005-08-25 | 2007-03-01 | Heraeus Kulzer Gmbh | Drug release system and its use |
US8360629B2 (en) | 2005-11-22 | 2013-01-29 | Depuy Spine, Inc. | Mixing apparatus having central and planetary mixing elements |
US20070184087A1 (en) * | 2006-02-06 | 2007-08-09 | Bioform Medical, Inc. | Polysaccharide compositions for use in tissue augmentation |
WO2008006083A2 (en) | 2006-07-07 | 2008-01-10 | Surmodics, Inc. | Beaded wound spacer device |
AU2007297097A1 (en) | 2006-09-14 | 2008-03-20 | Depuy Spine, Inc. | Bone cement and methods of use thereof |
US7923020B2 (en) * | 2006-09-29 | 2011-04-12 | Depuy Products, Inc. | Composite for implantation in the body of an animal and method for making the same |
AU2007311451A1 (en) | 2006-10-19 | 2008-04-24 | Depuy Spine, Inc. | Fluid delivery system |
EP1985317B1 (en) | 2007-04-24 | 2013-06-05 | Heraeus Kulzer GmbH | Spacer polymethyl methacrylate bone cement |
DE102007063613B4 (en) | 2007-04-24 | 2010-01-07 | Heraeus Kulzer Gmbh | Use of a spacer polymethyl methacrylate bone cement |
DE102007029098B4 (en) | 2007-04-24 | 2010-12-09 | Heraeus Kulzer Gmbh | Spacer polymethyl methacrylate bone cement and its use |
US20090111763A1 (en) * | 2007-10-26 | 2009-04-30 | Celonova Biosciences, Inc. | Loadable polymeric particles for bone augmentation and methods of preparing and using the same |
US20090110738A1 (en) * | 2007-10-26 | 2009-04-30 | Celonova Biosciences, Inc. | Loadable Polymeric Particles for Cosmetic and Reconstructive Tissue Augmentation Applications and Methods of Preparing and Using the Same |
US20090110730A1 (en) * | 2007-10-30 | 2009-04-30 | Celonova Biosciences, Inc. | Loadable Polymeric Particles for Marking or Masking Individuals and Methods of Preparing and Using the Same |
US20090110731A1 (en) * | 2007-10-30 | 2009-04-30 | Celonova Biosciences, Inc. | Loadable Polymeric Microparticles for Therapeutic Use in Alopecia and Methods of Preparing and Using the Same |
CA2719033C (en) * | 2007-12-07 | 2014-07-08 | Zimmer Orthopaedic Surgical Products, Inc. | Spacer mold and methods therefor |
US20090202609A1 (en) * | 2008-01-06 | 2009-08-13 | Keough Steven J | Medical device with coating composition |
AU2008363584B2 (en) * | 2008-10-29 | 2013-07-04 | Scott M. Sporer | Spacer molds with releasable securement |
US8409538B2 (en) * | 2008-12-04 | 2013-04-02 | Skeletal Kinetics Llc | Tricalcium phosphate coarse particle compositions and methods for making the same |
CA2798710C (en) | 2010-05-11 | 2019-08-27 | Venkat R. Garigapati | Organophosphorous, multivalent metal compounds, & polymer adhesive interpenetrating network compositions & methods |
WO2012158527A2 (en) | 2011-05-13 | 2012-11-22 | Howmedica Osteonics | Organophosphorous & multivalent metal compound compositions & methods |
EP2529764A1 (en) | 2011-05-31 | 2012-12-05 | Curasan AG | Biodegradable composite material |
US8834772B2 (en) | 2011-12-07 | 2014-09-16 | Biomet Manufacturing, Llc | Antimicrobial methacrylate cements |
US9155671B2 (en) | 2012-10-16 | 2015-10-13 | Surmodics, Inc. | Wound packing device and methods |
US10201457B2 (en) | 2014-08-01 | 2019-02-12 | Surmodics, Inc. | Wound packing device with nanotextured surface |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2501683A1 (en) * | 1975-01-17 | 1976-07-29 | Leitz Ernst Gmbh | BIOACTIVE COMPOSITE MATERIAL FOR PROSTHETIC PURPOSES AND METHOD FOR ITS MANUFACTURING |
DE2614170A1 (en) * | 1975-04-11 | 1976-10-21 | Glasrock Products | MATERIAL COMPOSITE PROSTHESIS |
DE2518153A1 (en) * | 1975-04-18 | 1976-10-28 | Sulzer Ag | MIXTURE USED FOR ANCHORING IMPLANTS IN THE BONE |
DE2620907A1 (en) * | 1976-05-12 | 1977-11-17 | Battelle Institut E V | ANCHORING FOR HIGHLY LOADED ENDOPROSTHESES |
DE2742128A1 (en) * | 1976-09-20 | 1978-03-23 | Inst Nat Sante Rech Med | BONE REPLACEMENT MATERIAL AND THEIR USE |
DE2821354A1 (en) * | 1977-05-20 | 1978-11-23 | Kureha Chemical Ind Co Ltd | MATERIAL DESIGN FOR IMPLANT PURPOSES |
DE2724814A1 (en) * | 1977-06-02 | 1978-12-07 | Kulzer & Co Gmbh | PRE-PRODUCT FOR THE PREPARATION OF BONE CEMENT |
DE2733394A1 (en) * | 1977-07-23 | 1979-02-01 | Riess Guido Dr | ARTIFICIAL TOOTH WITH IMPLANTABLE TOOTH ROOT |
US4141864A (en) * | 1974-03-15 | 1979-02-27 | University Of Virginia Alumni Patents Foundation | Osseous cement composition |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3609867A (en) * | 1969-03-10 | 1971-10-05 | Research Corp | Plastic bone composition |
US3787900A (en) * | 1971-06-09 | 1974-01-29 | Univ Iowa State Res Found | Artificial bone or tooth prosthesis material |
DE2320373B2 (en) * | 1973-04-21 | 1978-04-06 | Merck Patent Gmbh, 6100 Darmstadt | Antibiotic agent and its use as a plastic surgical material |
DE2511122B2 (en) * | 1975-03-14 | 1977-06-08 | PRE-PRODUCT FOR THE PREPARATION OF BONE CEMENT | |
DE2620890C3 (en) | 1976-05-12 | 1987-09-10 | Battelle-Institut eV, 6000 Frankfurt | Plastic mass based on sintered calcium phosphates for implantable bone replacement, bone composite or prosthesis anchoring materials |
JPS6050743B2 (en) * | 1976-06-02 | 1985-11-09 | 旭光学工業株式会社 | Apatite sintered body and its manufacturing method |
AR216922A1 (en) * | 1976-11-11 | 1980-02-15 | Merck Patent Gmbh | PROCEDURE FOR THE MANUFACTURE OF A SURGICAL ENVIRONMENT |
-
1979
- 1979-02-16 DE DE19792905878 patent/DE2905878A1/en not_active Withdrawn
-
1980
- 1980-01-22 EP EP80100293A patent/EP0016906B1/en not_active Expired
- 1980-01-22 AT AT80100293T patent/ATE9866T1/en not_active IP Right Cessation
- 1980-01-22 DE DE8080100293T patent/DE3069440D1/en not_active Expired
- 1980-02-15 US US06/121,772 patent/US4373217A/en not_active Expired - Lifetime
- 1980-02-15 ES ES488649A patent/ES8201181A1/en not_active Expired
- 1980-02-18 CA CA000345901A patent/CA1162851A/en not_active Expired
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4141864A (en) * | 1974-03-15 | 1979-02-27 | University Of Virginia Alumni Patents Foundation | Osseous cement composition |
DE2501683A1 (en) * | 1975-01-17 | 1976-07-29 | Leitz Ernst Gmbh | BIOACTIVE COMPOSITE MATERIAL FOR PROSTHETIC PURPOSES AND METHOD FOR ITS MANUFACTURING |
DE2614170A1 (en) * | 1975-04-11 | 1976-10-21 | Glasrock Products | MATERIAL COMPOSITE PROSTHESIS |
DE2518153A1 (en) * | 1975-04-18 | 1976-10-28 | Sulzer Ag | MIXTURE USED FOR ANCHORING IMPLANTS IN THE BONE |
DE2620907A1 (en) * | 1976-05-12 | 1977-11-17 | Battelle Institut E V | ANCHORING FOR HIGHLY LOADED ENDOPROSTHESES |
DE2742128A1 (en) * | 1976-09-20 | 1978-03-23 | Inst Nat Sante Rech Med | BONE REPLACEMENT MATERIAL AND THEIR USE |
DE2821354A1 (en) * | 1977-05-20 | 1978-11-23 | Kureha Chemical Ind Co Ltd | MATERIAL DESIGN FOR IMPLANT PURPOSES |
DE2724814A1 (en) * | 1977-06-02 | 1978-12-07 | Kulzer & Co Gmbh | PRE-PRODUCT FOR THE PREPARATION OF BONE CEMENT |
DE2733394A1 (en) * | 1977-07-23 | 1979-02-01 | Riess Guido Dr | ARTIFICIAL TOOTH WITH IMPLANTABLE TOOTH ROOT |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0087662A1 (en) * | 1982-02-25 | 1983-09-07 | MERCK PATENT GmbH | Pharmaceuticals deposition system |
GB2139095A (en) * | 1983-05-07 | 1984-11-07 | Friedrichsfeld Gmbh | Improvements in and relating to semi-implants |
EP0131291A1 (en) * | 1983-07-12 | 1985-01-16 | MERCK PATENT GmbH | Materials for implantation |
DE3325111A1 (en) * | 1983-07-12 | 1985-01-24 | Merck Patent Gmbh, 6100 Darmstadt | IMPLANTATION MATERIALS |
WO1985000291A1 (en) * | 1983-07-12 | 1985-01-31 | MERCK Patent Gesellschaft mit beschränkter Haftung | Implantation materials |
EP0159036A3 (en) * | 1984-04-19 | 1987-11-19 | Klaus Dr.Med.Dr.Med.Habil. Draenert | Anchoring means with coating for implants |
EP0159036A2 (en) * | 1984-04-19 | 1985-10-23 | Draenert, Klaus, Dr.med.Dr.med.habil. | Anchoring means with coating for implants |
EP0164483A1 (en) * | 1984-06-12 | 1985-12-18 | Oscobal Ag | Method of producing a bone replacement material |
WO1986001726A1 (en) * | 1984-09-10 | 1986-03-27 | MERCK Patent Gesellschaft mit beschränkter Haftung | Material containing carbonate apatite and use of carbonate apatite for implants |
EP0511686A2 (en) * | 1984-12-14 | 1992-11-04 | DRAENERT, Klaus, Dr.med. | Artificial bone and method for making it |
DE3445731A1 (en) * | 1984-12-14 | 1986-06-19 | Klaus Dr.med. Dr.med.habil. 8000 München Draenert | Material and use thereof |
US5522894A (en) * | 1984-12-14 | 1996-06-04 | Draenert; Klaus | Bone replacement material made of absorbable beads |
EP0511686A3 (en) * | 1984-12-14 | 1992-12-16 | Klaus Dr.Med. Draenert | Artificial bone and method for making it |
WO1986003667A1 (en) * | 1984-12-14 | 1986-07-03 | Klaus Draenert | Occlusion device made of surgical material |
WO1986003671A1 (en) * | 1984-12-14 | 1986-07-03 | Klaus Draenert | Bone replacement material and utilization thereof |
EP0202445A3 (en) * | 1985-04-18 | 1987-08-12 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Pharmaceutical deposition forms containing antitumour agents |
EP0202445A2 (en) * | 1985-04-18 | 1986-11-26 | MERCK PATENT GmbH | Pharmaceutical deposition forms containing antitumour agents |
EP0242672A3 (en) * | 1986-04-18 | 1990-01-17 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Tricalcium phosphate for use as implants |
EP0242672A2 (en) * | 1986-04-18 | 1987-10-28 | MERCK PATENT GmbH | Tricalcium phosphate for use as implants |
EP0425200A1 (en) * | 1989-10-19 | 1991-05-02 | Nobuo Nakabayashi | Bone cement composition, cured product thereof, implant material and process for the preparation of the same |
US5264215A (en) * | 1989-10-19 | 1993-11-23 | Nobuo Nakabayashi | Bone cement composition, cured product thereof, implant material and process for the preparation of the same |
WO1992006717A1 (en) * | 1990-10-19 | 1992-04-30 | Klaus Draenert | Starting material for the production of bone cement, process for producing the same and process for producing bone cement |
EP0705609A2 (en) | 1994-10-06 | 1996-04-10 | MERCK PATENT GmbH | Porous bone-replacing material |
US5650108A (en) * | 1994-10-06 | 1997-07-22 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Porous bone replacement materials |
DE102005023094A1 (en) * | 2005-05-13 | 2006-11-16 | Nies, Berthold, Dr. | Bioactive bone cement e.g. for implantation into bones, made by adding small amounts of polymerizable monomers containing anionic groups which cause cement surface to mineralize after being incubated in simulated body fluid |
CN101961506A (en) * | 2010-09-30 | 2011-02-02 | 深圳市第二人民医院 | Composite nano biological bone glue with osteogenesis inducing activity and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
DE3069440D1 (en) | 1984-11-22 |
ES8201181A1 (en) | 1982-01-16 |
US4373217A (en) | 1983-02-15 |
DE2905878A1 (en) | 1980-08-28 |
ES488649A0 (en) | 1981-12-01 |
EP0016906B1 (en) | 1984-10-17 |
ATE9866T1 (en) | 1984-11-15 |
CA1162851A (en) | 1984-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0016906B1 (en) | Bone cement and method for its production | |
DE102007015698B4 (en) | Implant material based on a polymer system and its use as well as application set | |
EP0920341B1 (en) | Process for producing bone cement containing active substances | |
DE19953771C1 (en) | Absorbable bone implant material and method for producing the same | |
DE60305036T2 (en) | HYDRAULIC CEMENT BASED ON CALCIUM PHOSPHATE FOR SURGICAL APPLICATIONS | |
AT401229B (en) | TWO-PHASE BONE CEMENT | |
DE69715824T2 (en) | METHOD FOR PRODUCING AN IMPLANTABLE COMPOSITE MATERIAL, MATERIALS PRODUCED THEREOF, AND KIT FOR IMPLEMENTING THE METHOD | |
DE69826451T2 (en) | Anesthetic bone cement | |
DE2917037C2 (en) | Parenterally medicinal, partially absorbable multi-component material based on polymeric substances | |
DE102010005956B4 (en) | Three-component bone cement and its use | |
EP1121161A1 (en) | Composition for implantation in the human and animal body | |
EP0177781B1 (en) | Bone cement and method for making it | |
EP1687040B1 (en) | Bioresorbable composite material | |
EP2630977A2 (en) | Bone cement in paste form | |
EP2236162A2 (en) | Bioactive bone cement and method for its production | |
EP1732618B1 (en) | Method for producing a bone implant material | |
WO1987000058A1 (en) | Bone cement | |
DE69431092T2 (en) | Medical cement, process for its production and its use | |
DE102010055759B4 (en) | Bone cement paste and its use | |
EP2482861B1 (en) | Bone cement and a method for producing same | |
EP3254709B1 (en) | Two component polymethacrylate bone cement in paste form | |
EP0123323B1 (en) | Use of difunctional acrylic and methacrylic esters for the preparation of bone cements | |
DE3220932C2 (en) | ||
EP4335466A1 (en) | Composition for the preparation of a bone substitute material, method for the preparation of a pharmaceutical active substance carrier, pharmaceutical active substance carrier and its use | |
WO1986001725A1 (en) | Bone cement and process for its manufacture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT NL SE |
|
17P | Request for examination filed |
Effective date: 19810319 |
|
ITF | It: translation for a ep patent filed | ||
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT NL SE |
|
REF | Corresponds to: |
Ref document number: 9866 Country of ref document: AT Date of ref document: 19841115 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 3069440 Country of ref document: DE Date of ref document: 19841122 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
ITTA | It: last paid annual fee | ||
EAL | Se: european patent in force in sweden |
Ref document number: 80100293.2 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19970109 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19970113 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 19970114 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19970115 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19970130 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19970131 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19970206 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19970318 Year of fee payment: 18 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980122 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980122 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980123 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY Effective date: 19980131 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980131 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980131 |
|
BERE | Be: lapsed |
Owner name: MERCK PATENT G.M.B.H. Effective date: 19980131 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980801 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 19980122 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 19980801 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19981001 |
|
EUG | Se: european patent has lapsed |
Ref document number: 80100293.2 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |